



Novel treatment approaches based on identification of 





In partial fulfilment of the requirements for the degree                          
"Doctor of Philosophy" 
In the Neuroscience Graduate Program 
At the Georg August University, Göttingen 












I hereby declare that this submission is my own work and that, to the best of my 
knowledge and belief, it contains no materials previously published or written by 
another person nor material which to a substantial extent has been accepted for 
the award of any other degree of the university or other institute of higher 























I am sincerely grateful to Prof. Dr. Dr. Hannelore Ehrenreich first of all for giving 
me the opportunity to work in her selective laboratory in such an amazing 
institute. I owe many thanks for her supervision and constant support throughout 
my PhD years. I would also like to thank for her amazing motivation and 
guidance in my PhD work.    
 
I owe many thanks to Prof. Anna-Leena Sirén who has helped me during the 
initial phase of my PhD. I am grateful for her comments, discussion and support. 
 
I would like to acknowledge Prof. Armin-Klaus Nave, Prof. Nils Brose and Prof. 
Ralf Heinrich for their contributions as members of my thesis committee. I am 
especially grateful to Prof. Klaus-Armin Nave for his advice, support and 
discussions. 
 
Many thanks to the members of the Neuroscience Program Coordination office 
Prof. Michael Hörner and Sandra Drube. I would especially like to thank Prof. 
Michael Hörner for providing extensive support throughout my PhD thesis.  
 
I would like to thank Dr. Imam Hassouna for his great help on setereological 
countings and analyses. I owe special thanks to Swetlana Sperling for her great 
technical assistance. I would like to thank Dr. Kostik Radyushkin for his support 
and guidance in behavior experiments. I also thank Dr. Martin Begemann, Dr. 
Claudia Bartels, Dr. Henning Krampe, Dr. Sabina Stawicki, Bartosz Adamcio, 
Ahmed el-Kordi for their help in many different aspects of my PhD life. I thank 
Kathrin Hannke and Anja Ronnenberg for assisting me in certain techniques. I 
acknowledge Wiebke Timner for dealing with all the administrative problems and 
for her continuous friendly smile. Once more, I thank all the members of the 
Clinial Neuroscience group for their amazing friendship and support through all 




Special thanks to my dearest friends Dr. Benjamin Cooper, Burcu Kasapoglu, Dr. 
Amit Agarwal and Schanila Nawaz for always being there for me. I would like to 
thank Ben who is a talented postdoc and a loving boyfriend. I am very happy to 
have my closest friend Burcu here with me and thank for her amazing friendship 
and for all the fun we had in and outside Göttingen. I thank Amit for enjoying the 
cloning with me and thank both Amit and Schanila for their amazing friendship 
and optimism.  
 
My deepest and warmest gratitude goes to my loving mother and my little sister 




















    TABLE OF CONTENTS 
 
1. INTRODUCTION TO THE SCIENTIFIC PROJECT ............................................ 1 
2. FOCUS OF THE PRESENT WORK ......................................................................... 7 
2.1 AIMS OF PROJECT I ..................................................................................................... 7 
2.2 AIMS OF PROJECT II.................................................................................................... 8 
2.3 AIMS OF PROJECT III .................................................................................................. 8 
3. EFFECT OF EPO ON HIPPOCAMPUS DEPENDENT MEMORY ................... 10 
UNDERSTANDING MECHANISMS OF EPO-INDUCED COGNITIVE 
IMPROVEMENT UNDER HEALTHY AND DISEASE CONDITIONS ................ 10 
3.1 OVERVIEW OF PROJECT I .......................................................................................... 10 
3.2 ORIGINAL PUBLICATION........................................................................................... 13 
4. MOLECULAR DETERMINANTS UNDERLYING RAPID CYCLING 
DISORDER AND NEW TREATMENT APPROACHES.......................................... 62 
4.1 OVERVIEW OF PROJECT II......................................................................................... 62 
4.2 ORIGINAL PUBLICATION........................................................................................... 66 
5. MORPHOLOGICAL AND CELLULAR CONSEQUENCES OF CHRONIC 
NEURODEGENERATION INDUCED BY AN EARLY UNILATERAL 
PARIETAL CRYO-LESION AND TREATMENT BY EPO .................................... 74 
5.1 OVERVIEW OF PROJECT III ....................................................................................... 74 
5.2 ORIGINAL PUBLICATION........................................................................................... 78 
6. SUMMARY ............................................................................................................... 107 
7. LITERATURE .......................................................................................................... 111 
8. LIST OF PUBLICATIONS ..................................................................................... 118 
9. CURRICULUM VITAE........................................................................................... 120 
1. Introduction to the scientific project 
 
The present cumulative thesis includes three original publications investigating 
new treatment strategies for neuropsychiatric diseases. The first paper focuses 
on erythropoietin (EPO) and its mechanisms of action on improving cognition 
under healthy and disease conditions i.e. schizophrenia. The second paper is a 
case study of a rapid cycling patient and explores molecular aspects of the 
disease leading to an alternative treatment approach for stabilization of the 
cycling behavior. The third paper is based on a traumatic brain injury model that 
leads to atrophy and cognitive impairment at an older age in mice. It explores the 
morphological consequences of atrophy induced by lesion and offers EPO as a 
neuroprotective agent to prevent lesion induced atrophy, cognitive impairment 
and late morphological changes in the brain. 
 
Two major psychiatric disorders, schizophrenia and bipolar disorder, were first 
characterized as dementia praecox and manic-depressive insanity respectively 
by Emil Kraepelin about a hundred years ago (Kendell, 1987). Schizophrenia is a 
disease in which higher brain functions and as a result, social behavior 
deteriorate and the patient suffers from auditory hallucinations, delusions, 
disorganized thinking and cognitive decline. It affects 0.4-0.6% of the population 
with an age of onset at around mid twenties (Bhugra, 2005). Cognitive deficits 
and behavioral abnormalities are already present from early childhood but the 
general characteristics of the disease appear in late teens. Twin studies have 
shown that heritability as well as environmental factors are important for the 
outcome of the disease (Prescott and Gottesman, 1993). Thus, it is a 
multifactorial disorder that has a combination of environmental and genetic 
causes.   
 
Another common psychiatric disease, bipolar disorder, is characterized by an 
abnormally elevated mood, referred to as mania, followed by periods of 
depression. It has a prevalence of 1.3-1.6% and the first major mood episode is 
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usually experienced during adolescence (Muller-Oerlinghausen et al., 2002). 
Manic and depressive episodes are mostly separated by periods of normal 
mood. However, in 10-30% of bipolar disease patients, mania and depression 
rapidly alternate. This condition is known as rapid cycling (Papadimitriou et al., 
2005). In bipolar disorder, symptoms of mania include mood elevation, 
grandiosity, overconfidence, decreased sleep, rapid speech, increased appetite, 
and libido and manic episodes are characterized by hospitalization, psychosis 
and functional impairment. Depressive episodes are usually longer and take over 
the lives of majority of bipolar patients (Thase, 2005). As in schizophrenia, 
neurocognitive impairments including disturbances in attention, memory and 
executive function, are core features of bipolar disorder (Thompson et al., 2005). 
Recent research has shown that bipolar disorder, like schizophrenia, might be a 
polygenic disease with more than one gene involved in its etiology (Barrett et al., 
2003; Baum et al., 2008).  
 
There are treatments available for reducing the symptoms of both schizophrenia 
and bipolar disorder but the diseases cannot be cured. Moreover, there is no 
drug available for preventing the cognitive impairment and thus increasing the 
quality of life for the patients of both diseases. The first-generation antipsychotic 
drugs, or typical antipsychotics, function as D2 dopamine receptor antagonists. 
They are used to treat positive symptoms of schizophrenia, such as 
hallucinations and delusions. However, they are not effective in treating negative 
symptoms, such as lack of motivation, anhedonia and cognitive dysfunction and 
patients suffer from adverse extrapyramidal side effects (Murphy et al., 2006). In 
1989, with the introduction of clozapine, typical antipsychotic drugs are replaced 
by atypical antipsychotics having less side effects and offering more effective 
treatment (Kane et al., 1988). They act by inhibiting D2 dopamine as well as 
serotonin (5HT2A) receptors (Snyder and Murphy, 2008). After clozapine, the next 
15-20 years in schizophrenia research was devoted to developing clozapine-like 
atypical antipsychotics that are safer and better tolerated. Development of 
additional atypical drugs like risperidone, olanzapine, quetiapine, and ziprasidone 
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did not fulfill the expectations since these drugs as well as clozapine are unable 
to treat negative symptoms of the disease (Keefe et al., 1999). Moreover, though 
they do not lead to extrapyramidal side effects, atypical antipsychotics still have 
their own side effect burden such as weight gain (Allison et al., 1999) and 
metabolic syndrome (Newcomer et al., 2002).  
 
For bipolar disorder, the most commonly used mood-stabilizing drug is lithium. It 
has been effective in reducing the symptoms of the disease and preventing 
suicide (Fountoulakis et al., 2007).  A group of anticonvulsants and anti-epileptic 
drugs, such as valproic acid and carbamazepine, are among the most commonly 
used mood-stabilizers in bipolar disease (Sachs and Thase, 2000). Second-
generation atypical antipsychotic drugs have increasingly begun to be used for 
stabilization of manic phases (Surja et al., 2006). Once again, limitations of the 
medication are inadequate effectiveness, inability to treat target symptoms and 
adverse side effects (Perlis et al., 2006). Moreover, presence of different 
subtypes of the disease, such as rapid cycling disorder, provides more challenge 
for development of an effective treatment. Rapid cycling patients are poor 
responders to treatment with either lithium or anticonvulsants (Calabrese et al., 
2005; Tondo et al., 2003). Interestingly, there are even increasing yet 
inconclusive evidence that antidepressants may trigger or worsen rapid-cycling 
disorder (Ghaemi et al., 2003; Wehr et al., 1988).  
 
Understanding mechanisms and molecular determinants underlying 
pathophysiology of neuropsychiatric disorders is important for development of 
novel therapies for these diseases with high prevalence and increased risk of 
mortality. In order to study the pathophysiology, it is inevitable to combine genetic 
and environmental approaches for these multifactorial disorders for developing 
animal models. Traumatic brain injury (TBI) is one of the epigenetic risk factors 
contributing to the outcome of personality changes (Gualtieri and Cox, 1991; 
Lannoo et al., 1997), depression (Fedoroff et al., 1992; Rosenthal et al., 1998), 
schizophrenia (Malaspina et al., 2001; Silver et al., 2001), mania (Shukla et al., 
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1987; Starkstein et al., 1987) and neurodegenerative disorders like Alzheimer’s 
and Parkinson’s diseases (Bower et al., 2003; Nemetz et al., 1999; Stern, 1991). 
About 15% of those afflicted with TBI in their lives appear to be symptomatic for 
other neurological disorders (Alexander, 1995). The outcome of TBI would 
depend on previous vulnerabilities, the extent of the injury and the reaction of the 
brain to the injury. Studies show that the young and the old are at higher risk for 
suffering the consequences of TBI (Kraus and Nourjah, 1988).  
 
Mechanisms leading to cognitive impairment and cognitive related disorders after 
TBI remain to be elucidated. Depending on the extent of concussion, damage 
might include swelling of the brain, hypoxia or diffuse axonal injury. Primary brain 
injury mechanisms might involve damage on axons and microvasculature leading 
to formation of microhemorrhages that disrupt blood supply in certain regions of 
the brain. Damage on axons might lead to Wallerian degeneration or neuronal 
degeneration, and subsequent depolarization of neurons in affected areas or 
even at remote sites (Hall et al., 2008; Hurley et al., 2004; Povlishock, 1993). 
This might lead to an increase in the activity of N-methyl-D-aspartate (NMDA) 
receptors and result in an excess release of glutamate, excitotoxicity, free radical 
formation and oxidative stress (Faden et al., 1989; Giza et al., 2006). Neuronal 
death at the site of injury might mediate release of cytokines initiating pro-
inflammatory reactions with the induction in expression of interleukins and other 
pro-inflammatory mediators leading to an inflammatory reaction. Inflammation 
initiates the beginning of the second stage of brain injury or secondary brain 
injury. Increased permeability of the blood-brain barrier followed by invasion of 
macrophages are additional events in the secondary injury cascade of TBI (Potts 
et al., 2006).  
 
Neuroimaging studies in posttraumatic patients have reported cortical and 
subcortical atrophy, ventricular enlargement and white matter injury (Anderson et 
al., 1996; Arciniegas and Silver, 2001; Bigler, 2003). These findings supported 
the notion that TBI is associated with reductions in the volumes of cerebral 
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structures important for maintenance of cognitive functions. Events occurring in 
response to acute injury are extensively studied however, at present, efficient 
pharmacotherapy for TBI is lacking and most importantly, mechanisms leading to 
the late consequences of TBI and/or cognitive impairment and neurological 
disorders are unkown.  
 
Despite having different disease characteristics, TBI and cognitive disorders 
share common pathophysiological features such as neuronal or axonal injury, 
oxidative stress and inflammation. Because of these common but diverse 
functional disturbances, cognitive disorders remain untreated by the application 
of a single drug treatment. Therefore, it is essential to develop therapeutic 
strategies that aim at treating more than one aspect of the disease and 
supporting the regenerative potential of the brain. Such a natural protein 
hormone, which has been used to treat anemia since more than a decade, is the 
glycoprotein erythropoietin (EPO). EPO is a 30.4 kDa glycoprotein that regulates 
red blood cell differentiation by inhibiting apoptosis of erythroid progenitors in 
bone marrow (Koury and Bondurant, 1992). It is a member of the class I cytokine 
superfamily which also includes interleukins (IL-2, -3, -4, -5, -6), granulocyte 
colony stimulating factor and granulocyte-macrophage colony stimulating factor 
(GM-CSF), leukemia inhibitory factor and ciliary neurotrophic factor. EPO is 
predominantly produced in the fetal liver and adult kidney (Dame et al., 1998; 
Zanjani et al., 1977). The finding that EPO and its receptor (EPOR) are 
expressed in the brain (Sasaki et al., 2001) led to the notion that EPO exerts 
direct, hematopoiesis-independent effects on the nervous system.  
 
EPO functions by binding to an erythropoietin receptor (EPOR), which is a 
glycosylated and phosphorylated transmembrane polypeptide with the molecular 
weight of 72-78 kDa. Like other cytokine receptors, EPOR contains 2 β sandwich 
domains, D1 (N-terminal) and D2 (carboxy-terminal) (Syed et al., 1998). Due to 
the unique structural features of the N-terminal and C-terminal domains, EPOR 
belongs to a novel class of receptors called the hematopoietin receptor 
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superfamily, which includes human growth hormone and prolactin receptors 
(Krantz, 1991). After EPO binding, EPO receptors homodimerize triggering the 
activation of several signal transduction pathways. The first step of EPO-induced 
intracellular signaling is the activation of the Jak2 tyrosine kinase, which is 
constitutively associated with the EPOR. Jak2 activation leads to the 
phosphorylation of 8 tyrosines located within the intracellular domain of EPOR. 
These serve as docking sites for other various intracellular proteins, which then 
can also become phosphorylated and activated. This phosphorylation cascade 
activates several intracellular pathways, including signal transducer and activator 
of transcription (STAT), Ras–mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol 3-kinase (PI3K) pathways (Brines and Cerami, 2005).  
 
Discovery of EPO to increase neuromuscular strength (Sobh et al., 1992), 
cognitive functions (Nissenson, 1989) and quality of life (Wolcott et al., 1989) in 
anemic patients has led to the notion that EPO might be involved in neuronal 
protection. One of the first studies to show EPO-induced neuroprotection was 
increased neuronal survival after hypoxia by EPO addition in culture (Konishi et 
al., 1993). Different neuroprotective properties of EPO has rendered this growth 
hormone to be used as an ideal pharmacotherapeutic agent to offer 
neuroprotection in neurological disorders with a variety of pathophysiological 
features resulting in a common characteristic i.e. cognitive impairment. EPO has 
been shown to have anti-apoptotic (Siren et al., 2001), anti-oxidative 
(Chattopadhyay et al., 2000; Genc et al., 2002), anti-inflammatory (Agnello et al., 
2002; Villa et al., 2003), neurotrophic (Campana and Myers, 2001) and 
angiogenetic (Sasaki et al., 2001) properties . Moreover, it is known to induce 
stem cell differentiation (Chen et al., 2007; Gonzalez et al., 2007; Jelkmann, 
2000; Shingo et al., 2001). Development of animal models of neurological 
diseases in order to directly evaluate neuroprotective functions of EPO in vivo 
and deciphering mechanisms of action of this multifactorial compound will open a 
new era in treatment and understanding of neuropsychiatric disorders.  
 
 6
2. Focus of the present work 
 
The thesis includes 3 original publications that investigate mechanisms leading to 
neuropsychiatric disorders and present novel treatments for these diseases. 
 
2.1 Aims of project I 
 
The first original publication focuses on mechanisms of EPO action and how it 
improves cognition in neuropsychiatric disorders like schizophrenia. For the 
experiments, young (28 days old) C57BL6 mice, primary hippocampal neuronal 
cultures from mice at embryonic day 17 (E17) and autaptic hippocampal cultures 
from postnatal day 0 (P0) mice were used.  
 
The first aim of the study was to develop a model to show that EPO improves 
cognition under healthy conditions. This would allow us to search for the 
mechanisms of EPO action in the healthy brain where interference from disease 
associated conditions could be excluded. Young healthy mice at the age of 28 
days old were subjected to EPO injections for 3 weeks every other day. Mice 
were then run through an extensive behavioral test battery at different time points 
to assess EPO action on hippocampus dependent memory and to rule out EPO 
effect on other parameters.  
 
The second aim was to find out how EPO improves cognitive function. Effect of 
EPO on synaptic transmission and synapse numbers was investigated using 
hippocampal slices and sections from EPO-treated mice. Synaptic function was 
investigated at the network level with primary hippocampal cultures and at the 
single cell level with autaptic hippocampal neurons.  
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2.2 Aims of project II 
 
The second original publication focuses on a rare form of bipolar disorder, rapid 
cycling syndrome. Peripheral blood mononuclear cells (PBMC) were isolated 
from the blood of a rapid cycling patient at different disease stages and episodes. 
RNA isolated from PBMC was used for expression analysis.  
 
The first aim of the study was to identify genes that were differentially regulated 
at manic and depressed phases. RNA isolated from PBMC of the patient at 
different episodes throughout years was subjected to microarray analysis. Genes 
identified in this way were further confirmed by quantitative real-time polymerase 
chain reaction (qRT-PCR).  
 
The second aim was to develop a treatment approach based on differential gene 
expression in manic and depressed phases. The treatment was designed to keep 
the patient at the most stable condition by improving depressed as well as manic 
symptoms. The patient was controlled through psychopathological ratings before 
and during the treatment period.  
2.3 Aims of project III 
 
The third original publication investigates the morphological consequences of a 
unilateral parietal lesion in mice which develop chronic neurodegeneration devoid 
of gliosis over time. Pathophysiological findings in this mouse model mimics 
those observed in schizophrenia and serves as a model to understand the 
mechanisms leading to the outcome of this disease. C57BL6 mice at the age of 
28 days were used for lesion experiments. Mice were analyzed at time points 24 
hours and 11 months after lesion. 
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The first aim of the study was to analyze the histological aspects of global 
atrophy induced by a unilateral cortical lesion at a young age in mice. Chronic 
neurodegenerative changes appear many months after lesion and mimic those in 
schizophrenia. A detailed histological analysis based on stereology would serve 
to understand the mechanisms leading to the observed atrophy. 
 
EPO treatment right after lesion provided beneficial effects in preventing the 
outcome of cortical atrophy and the cognitive impairment observed in lesioned 
mice. The second aim of the study was based on understanding how EPO 
prevented atrophy and which pathophysiological aspects on the way to atrophy 
and cognitive impairment could be overcome by early EPO treatment.  This study 


















3. Effect of EPO on hippocampus dependent memory 
Understanding mechanisms of EPO-induced cognitive 
improvement under healthy and disease conditions 
 
3.1 Overview of project I 
EPO is a hematopoietic growth factor that was initially used for treating anemic 
patients. Observation of improved cognition in EPO-treated patients and that 
EPO and its receptor are expressed in the brain opened up a new era in EPO 
research. Since then, many studies showed that EPO acts in an anti-apoptotic, 
anti-inflammatory, anti-oxidative and stem-cell modulatory fashion under 
pathological conditions. EPO has also been shown to promote neurite outgrowth 
and axonal repair (Campana and Myers, 2001; Celik et al., 2002; Konishi et al., 
1993; Shingo et al., 2001; Siren et al., 2001). These studies further supported the 
notion that EPO exerts neuroprotective effects independent of its hematopoietic 
function.  
 
Effects of EPO on cognition has been shown in different animal models of 
disease including ischemia/hypoxia and traumatic brain injury (Catania et al., 
2002; Kumral et al., 2004; Siren et al., 2006). A double-blind, placebo-controlled, 
proof-of-principle (phase II) study has shown for the first time beneficial effects of 
EPO in improving cognitive functions in chronic schizophrenic patients 
(Ehrenreich et al., 2007b). Moreover, an exploratory open label study (phase 
I/IIa) in chronic progressive multiple sclerosis (MS) patients has shown 
improvement in motor and cognitive function upon EPO treatment. In these 
studies, there was hardly any detectable hematopoietic response to EPO 
(Ehrenreich et al., 2007a).  
 
Despite EPO’s proven beneficial role in neurological diseases, its mechanisms of 
action to improve cognitive function and its effect on cognition under healthy 
conditions are still unknown. In order to investigate EPO’s action on cognitive 
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functions under healthy as well as disease state, we have developed an 
experimental condition where systemic EPO treatment for 3 weeks in mice has 
led to a  significant improvement in hippocampus dependent memory task, fear 
conditioning. For all the experiments, young (28 days old) and healthy C57BL6 
mice were used. EPO was applied intraperitoneally every other day (11 injections 
in total). EPO-treated mice showed a significant improvement in hippocampus 
dependent contextual memory task assessed by fear conditioning test 1 week 
after the last injection. EPO-treated animals were still significantly better in this 
task compared to the placebo-treated controls 3 weeks after cessation of the 
treatment. Interestingly, during this time, hematocrit levels were comparable 
between the groups. Moreover, EPO’s action on cognition was rather selective 
since EPO-treated mice did not differ from controls in terms of motor 
performance, anxiety and exploratory behavior.  
 
In order to understand the mechanism of EPO action on cognitive function, we 
performed electrophysiological, histological as well as biochemical analysis to 
assess EPO-induced changes in synaptic function. Hippocampal slices from 
mice treated with EPO for 3 weeks and killed 1 week after cessation of treatment 
were used for electrophysiological analysis. Field excitatory postsynaptic 
potentials (fEPSPs) were evoked by placing the stimulation electrode in stratum 
radiatum  of the CA3/CA1  region and the recording electrode in the stratum 
radiatum of the CA1 region. Electrophysiological analysis revealed a significant 
enhancement of long term potentiation (LTP), short term potentiation (STP) and 
short term depression (STD) in slices obtained from EPO-treated mice compared 
to controls. Whole-cell patch-clamp recordings on pyramidal cells of CA1 
hippocampal region showed that, upon EPO treatment, the frequency of 
spontaneous inhibitory postsynaptic currents (sIPSCs) increased whereas the 
frequency of spontaneous excitatory postsynaptic currents (sEPSCs) decreased.  
 
The results obtained in hippocampal slices were further supported by multi-
electrode array (MEA) measurements in vitro using primary hippocampal 
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cultures. Hippocampal neurons obtained from mice at E17 were treated with 
EPO for 3 weeks starting from day 5 in culture. Upon maturation of the culture, 
the number of silent channels decreased in the placebo-treated cultures whereas 
EPO treatment prevented this decrease. Moreover, 2-3 weeks after cessation of 
EPO treatment, the number of bursting channels were higher in EPO-treated 
cultures compared to controls. Whole-cell patch-clamp recordings in autaptic 
hippocampal neurons treated with EPO at day 7 in culture and analyzed at day 9-
14 showed a significant reduction in EPSC amplitude and readily-releasable pool 
size upon EPO treatment.  
 
To assess whether EPO has any effects on synapse numbers, we counted 
synapses on hippocampal sections and in autaptic cultures at the same time 
points used for electrophysiological analysis. Analysis of synapsin1 positive 
presynaptic density in different regions of hippocampus and in autaptic cultures 
revealed no difference upon EPO and placebo treatments. Thus, EPO exerted its 
effects on hippocampal synaptic function not by affecting the synapse number 
but rather by shifting the balance between excitatory and inhibitory transmission. 
EPO might selectively enhance the efficiency of selected neuronal networks 
whereas keeping the others silent.  
 
In summary, with this publication, we have shown, for the first time, action of 
EPO on modulating synaptic plasticity by increasing inhibitory and decreasing 
excitatory transmission. EPO exerts its effects on synaptic transmission in 
parallel to increasing LTP and improving cognition. By enhancing the activity of 
selected synapses while keeping the others silent and in this way, affecting the 
synaptic function but not the number, EPO works in rather an unexpected way to 
improve cognition. Further experiments that would help us to understand EPO 
action on synapse in more detail will also help to decipher the mechanisms 
leading to cognitive disruption in neuropsychiatric disorders and to develop new 




3.2 Original publication 
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Abstract  
BACKGROUND: Erythropoietin (EPO) improves cognition of human subjects in the 
clinical setting by as yet unknown mechanisms. We developed a mouse model of 
robust cognitive improvement by EPO to obtain the first clues of how EPO influences 
cognition, and how it may act on hippocampal neurons to modulate plasticity. 
RESULTS: We show here that a 3-week treatment of young mice with EPO 
enhances long-term potentiation (LTP), a cellular correlate of learning processes in 
the CA1 region of the hippocampus. This treatment concomitantly alters short-term 
synaptic plasticity and synaptic transmission, shifting the balance of excitatory and 
inhibitory activity. These effects are accompanied by an improvement of 
hippocampus dependent memory, persisting for 3 weeks after termination of EPO 
injections, and are independent of changes in hematocrit. Networks of EPO-treated 
primary hippocampal neurons develop lower overall spiking activity but enhanced 
bursting in discrete neuronal assemblies. At the level of developing single neurons, 




without changing the number of synaptic boutons, consistent with prolonged 
functional silencing of synapses.  
CONCLUSIONS: We conclude that EPO improves hippocampus dependent memory 
by modulating plasticity, synaptic connectivity and activity of memory-related 
neuronal networks. These mechanisms of action of EPO have to be further exploited 







The hematopoietic growth factor erythropoietin (EPO) has long been observed to 
exert beneficial effects on cognition. Upon introduction of recombinant human EPO 
into the clinic, cognitive improvement of patients with chronic renal failure was noted 
during EPO treatment, but attributed to its hematopoietic effects (for review see [1-
4]). Indeed, anemia after isovolemic hemodilution, induced in healthy volunteers, 
impairs cognitive performance, which is completely restored by subsequent 
autotransfusion [5]. 
 
However, the finding that EPO and its receptor (EPOR) are expressed in the brain [6, 
7] (for review see also [1, 3, 8-11]) led to the notion that EPO exerts direct, 
hematopoiesis-independent effects on the nervous system. The manufacturing of 
EPO analogues with no hematopoietic but potent neuroprotective properties, e.g. 
CEPO (carbamoylated EPO) [12], delivered proof-of-principle that brain effects of 





Beneficial effects of EPO on cognitive functioning have been shown in different 
animal models of neuropsychiatric diseases, e.g. on place navigation after global 
ischemia or neurotrauma [13-17]. In a recent double-blind, placebo-controlled, proof-
of-concept study in chronic schizophrenic patients, we showed that EPO improved 
schizophrenia-relevant cognitive performance independently of its hematopoietic 
effects. In fact, EPO turned out to be the first compound to exert a selective and 
lasting beneficial effect on cognition in schizophrenia [18]. Similarly, an increase in 
cognitive performance upon EPO in patients with chronic progressive multiple 
sclerosis occurred independently of changes in hemoglobin levels, and persisted for 
months after termination of EPO treatment [4, 19]. 
 
Recently, the application of a single high intravenous dose of EPO in healthy human 
volunteers was reported to enhance the functional MRI-detectable hippocampus 
response during memory retrieval 1 week later, before any effect on hemoglobin was 
measured [20]. However, data on hippocampus dependent memory in healthy human 
subjects upon EPO are still missing. Altogether, little is known about potential 
cognitive effects of EPO in healthy individuals. Hengemihle et al. [21] reported that 19 
weeks of low-dose EPO treatment increased spatial memory performance, and a 
conditioned learning task, taste aversion, was enhanced by a single high-dose 
injection of EPO in healthy mice [22]. 
 
In summary, the currently available data clearly indicate that EPO can improve 
cognitive function of both rodents and man by directly acting on the nervous system. 
To be able to fully exploit this beneficial cognitive effect of EPO for treatment of 




EPO action in healthy brain, where interference of disease-related effects can be 
excluded. Here, we systematically addressed this problem. We developed a reliable, 
robust model for improvement of cognition by EPO in healthy mice and examined 
correlated effects of EPO on hippocampal synaptic transmission and 
learning/memory-relevant synaptic plasticity. Further, we analyzed effects of EPO on 
cultured hippocampal neurons at network and single cell levels. Our data indicate 
that EPO improves memory by modulating synaptic connectivity of memory-related 
neuronal networks within the hippocampus.  
 
Results  
EPO improves hippocampus dependent memory in healthy young mice 
First goal of this study was to define an experimental condition to test potential 
abilities of EPO to improve cognitive functions. We used young (28 day old) male 
mice. In our experimental set-up with 11 intra-peritoneal EPO versus placebo 
injections (5000 IU/kg) every other day for 3 weeks (Figure 1), EPO-treated mice 
showed significant improvement of contextual memory in fear conditioning 1 week 
after the last injection, when tested 72 h after training in the same context (Figure 1, 
Exp. 1, Figure 2a). This effect was still measurable 3 weeks after cessation of EPO 
treatment but had disappeared after 4 weeks (Figure 1, Exp. 2 and Exp. 3; Figure 
2b,c). In contrast, EPO had no effect on cued memory (Figure 2a-c; all P>0.05). 
Whereas at 1 week after termination of treatment, hematocrit was still increased in 
EPO-treated mice (control mice: 36.5±0.84%, N=8; EPO mice: 53.3±1.34%, N=10; 
P<0.0001), there was no difference anymore between groups at 3 weeks (control 
mice: 39.4±1.19%, N=14; EPO mice: 40.8±0.92%, N=13; P=0.338), indicating that 





In two additional experiments, EPO was given only three times either at the 
beginning or at the end of the 3-week treatment period while the respective other 
eight injections consisted of placebo. In this setting, no improvement in cognitive 
performance was obtained (data not shown), suggesting that a certain amount of 
EPO treatment is required for improving cognition.  
 
The effect of EPO on hippocampus dependent (contextual) memory was selective. 
There was no EPO effect on anxiety, spontaneous activity, exploratory behavior, and 
motor performance (Figure 2d-g; all P>0.05). Time spent in open arms of elevated 
plus maze (Figure 2d) and time spent in the three different zones of open field was 
similar in both groups (Figure 2e). Total distance traveled in open field did not differ 
between groups nor did exploratory activity in hole board test (Figure 2e,f). Over two 
days of rota-rod testing, both groups did not differ in falling latency (Figure 2g), 
indicating that motor performance and motor learning were comparable. Taken 
together, EPO treatment over 3 weeks leads to selective and long-lasting 
improvement of hippocampus dependent (but not of global) memory in healthy mice, 
independent of hematopoietic effects. 
 
Synaptic plasticity is significantly increased at Schaffer collateral CA1 
synapses in EPO-treated mice 
One likely explanation for the selective improvement of contextual memory would be 
a direct influence of EPO on synaptic plasticity in the hippocampus. We therefore 
investigated the effect of EPO in acute hippocampal slices from mice at 1 week after 
the last injection (Figure 1, Exp. 4). We first performed extra-cellular recordings of 
field excitatory postsynaptic potentials (fEPSPs). Input-output curves were obtained 




Schaffer collaterals with increasing stimulation strengths (Figure 3a,b). Average of 
fEPSP slopes (Figure 3b) between stimulus intensities of 110-150 µA from all slices 
yielded no difference between control and EPO groups. Half-maximal stimulation 
strength was also comparable (Figure 3b, inset). Thus, EPO treatment for 3 weeks, 
followed by a treatment-free week, does not alter basal excitability.  
 
We then measured paired-pulse facilitation (PPF), the shortest form of plasticity at 
many synapses [31], at different inter-stimulus intervals (25-200 ms) in the Schaffer 
collateral CA1 pathway as ratio of the second fEPSP slope to the first fEPSP slope. 
Slices from EPO mice showed significantly enhanced paired-pulse facilitation at inter-
stimulus intervals 25-150 ms (Figure 3c,d). Next, the effect of EPO on short-term 
potentiation (STP) and long-term potentiation (LTP) at the Schaffer collateral CA1 
pathway was examined (Figure 3e-h). The magnitude of STP was defined as the 
maximal responses within the first minutes after induction by a train of 100 Hz stimuli. 
STP was significantly enhanced in slices of EPO mice compared to control (Figure 
3f,g). Furthermore, the magnitude of LTP, determined as the average of responses 
between 50 and 60 min after induction by a train of 100 Hz stimuli, was also 
enhanced in slices of EPO mice compared to control (Figure 3f,h).  
 
Another form of synaptic plasticity is long-term depression (LTD). We determined the 
effect of EPO treatment on short-term depression (STD) and LTD at Schaffer 
collateral CA1 pathway (Figure 3i-l). Magnitude of STD was defined as maximal 
responses within the first minutes after induction by a train of 900 stimuli (1 Hz). We 
found that STD was significantly enhanced in slices of EPO mice compared to control 
(Figure 3j,k). On the other hand, the magnitude of LTD, determined as average of 




not significantly different in slices of EPO mice compared to control (Figure 3j,l). 
Collectively, these data show that EPO modulates synaptic plasticity and LTP in the 
hippocampus, but has no significant effect on LTD. 
 
EPO differentially influences inhibitory and excitatory synaptic transmission in 
the Schaffer collateral CA1 pathway 
To study cellular mechanisms of EPO action, we performed whole-cell patch-clamp 
recordings on CA1 pyramidal neurons in acute hippocampal slices from mice at 1 
week after the last injection (Figure 1, Exp. 4; Figure 4a-f). Compared to control mice, 
the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) in CA1 
pyramidal neurons of EPO mice was increased, while the amplitude of sIPSCs was 
unchanged (Figure 4b,c). In contrast, EPO led to a significant decrease of both 
amplitude and frequency of spontaneous excitatory postsynaptic currents (sEPSCs) 
in CA1 pyramidal neurons (Figure 4e,f). Importantly, there were no significant 
differences in input resistance or basic noise level between neurons of control and 
EPO mice (data not shown). Thus, EPO modulates inhibitory and excitatory synaptic 
transmission inversely.  
We wondered whether the neurophysiological changes found in hippocampal slices 
upon EPO treatment would be due to alterations in total volume or synapse counts in 
the involved areas, CA1 and CA3. Neither volume of CA1 (control: 3.97±0.11 mm3, 
N=9; EPO: 4.02±0.16 mm3, N=10; P=0.81) nor CA3 (control: 3.29±0.21 mm3, N=8; 
EPO: 3.56±0.25 mm3, N=10; P=0.42), nor total hippocampal volume (control: 
9.54±0.34 mm3, N=8, versus EPO: 9.74±0.39 mm3, N=10; P=0.71) were significantly 
different. Moreover, density of synaptic boutons in CA1 (control: 1.28±0.08 




0.71±0.13 boutons/µm2, N=7; EPO: 0.78±0.08 boutons/µm2, N=9; P=0.61) was not 
changed. Quantitative RT PCR and/or Western blotting using extracts of whole 
hippocampus did not reveal differences in expression of synaptic proteins 
(synapsin1, synaptophysin), postsynaptic receptor proteins (GABAA1,2,3,4; 
NMDAR1, R2A, R2B) or BDNF, as potential mediating neurotrophic factor [20, 32] 
(data not shown).  
 
EPO modulates spontaneous electrical network activity in primary 
hippocampal neurons as determined by multi-electrode measurements 
Above data demonstrated distinct and long-lasting effects of temporary high-dose 
EPO treatment on hippocampus dependent memory and synaptic plasticity in 
hippocampal slice preparations. As the peritoneal applications of EPO might have 
caused indirect effects on nerve cells, we next studied primary hippocampal cultures. 
We tested whether chronic EPO treatment, extending from an advanced 
developmental stage (day 5 in culture) to over 3 weeks leads to alterations in 
spontaneous neuronal network activity, and whether such changes would persist 
upon cessation of EPO treatment.  
 
First, our long-term cultures were characterized regarding morphological appearance 
(Figure 5a), total cell numbers (day 10: control: 202.4±11.03, N=6; EPO: 
191.0±8.834, N=6; P=0.436; day 30: control: 147.9±26.26, N=6; EPO: 152.8±27.87, 
N=6; P=0.902), and relative contribution of different cell types (Figure 5b). In none of 
these parameters were differences upon EPO found at days 10 or 30 in culture. Also, 
quantitative RT PCR and protein expression, determined by Western blotting, failed 




time points tested (days 8, 14, and 30). Thus, EPO treatment did not cause changes 
in morphology under our culture conditions.  
 
Figure 5c illustrates primary hippocampal neurons grown on multi-electrode array 
(MEA) dishes. Group statistics for spontaneous electrical activity in the MEAs are 
presented in Figures 5d and e, contrasting silencing (number of channels with <5 
spikes per 2 min) and bursting behavior (percentage of strongly bursting channels of 
all active channels, with strongly bursting channels defined as channels with a 
coefficient of variation >2.6). With increasing age and maturation of culture, the 
number of silent channels decreased in control MEAs, as expected (Figure 5d). This 
was not the case in EPO cultures. Whereas during the treatment phase itself, 
cultures behaved largely similarly (weeks 3 and 4 with P=0.41 and P=0.18, 
respectively), differences became obvious at later time points (weeks 5 through 7 
with P=0.047, P=0.0043 and P=0.0043, respectively). This indicates that temporary 
EPO treatment causes a significant number of channels to remain silent for an 
extended period after cessation of EPO addition to cultures. 
 
The bursting channel analysis, presented in Figure 5e, showed that EPO provoked a 
consistently higher number of bursts in hippocampal cultures, obvious only at late 
time points, i.e. 2-3 weeks after termination of EPO treatment. This effect (expressed 
as percentage of all active channels in order to exclude the influence of silencing) 
was less pronounced as compared to the silencing effect of EPO. Whereas medians 
at week 6 were not yet significantly different (P=0.10), difference reached significance 
at week 7 (P=0.019). Together, the trend of weeks 6 and 7, when compared with the 




increase as a late consequence of transient EPO treatment, in parallel with the 
persistently high percentage of silent channels. 
 
Reduction of synaptic vesicle priming and transmitter release in the EPO pre-
treated neurons  
The finding of long-lasting EPO-induced dampening of spontaneous electrical activity 
in our primary hippocampal cultures together with a selective increase in bursting 
activity following EPO treatment prompted us to test individual neurons. We 
examined the effect of EPO in hippocampal autaptic cultures [30], to directly assess 
the EPO effect on presynaptic transmitter vesicle exocytosis and postsynaptic 
receptor responses. Autaptic neurons are neurons forming synapses on themselves, 
making electrophysiological stimulation and respective effect determination 
(recording) simple. Cultures were treated with EPO (0.3 IU/ml = 10-10 M) or the 
respective buffer solution only once at day 7 and then measured from days 9 to 14. 
There were no morphological differences detectable upon treatment, and sizes of 
somata as estimated by measurement of whole cell capacitance were comparable 
between EPO-treated and control neurons (control neurons: 49.61±2.75pF, N=54; 
EPO neurons: 46.0±2.73pF, N=49; P=0.355).  
 
Evoked excitatory postsynaptic current (EPSC) amplitudes in EPO-treated neurons 
were reduced to about 60% of control (Figure 6a), confirming the data obtained in 
acute slices (Figure 4e). This EPSC reduction was due to a parallel reduction in pool 
size of fusion-competent and primed (readily releasable) vesicles, whose release can 
be triggered by hypertonic solution containing 0.5 M sucrose [33]. EPO neurons 
showed a drastic reduction in readily releasable pool size to 60% of control (Figure 




single EPSC by the charge transfer measured during readily releasable pool release, 
was not different between control and EPO neurons (P=0.4116; Figure 6c). To test 
whether the reduction of neurotransmitter release in EPO neurons can be attributed 
to a reduction in quantal size, we analyzed miniature EPSCs (mEPSC). mEPSC 
frequency in EPO neurons was reduced to about 50% of control, without changes in 
mEPSC amplitudes (P=0.5817; Figure 6d,e). The lack of a difference in 
NMDA/AMPA ratio indicates a comparable maturation state of cultures (Figure 6f). 
Using trains of action potentials we estimated the efficiency of Ca2+ triggered release. 
In general, vesicular release probability closely correlates with depression and 
steady-state level of EPSC amplitude sizes during high frequency stimulation. We 
therefore monitored EPSC amplitudes during 50 consecutive action potentials 
applied at a frequency of 10 Hz. EPO and control neurons showed regular moderate 
depression of EPSC amplitudes (control: about 38%, N=60; EPO: depression at the 
end of train about 35%, N=60, Figure 6g). Stability of EPSC amplitudes during short-
term plasticity, which is due to the quantitative balance between priming of synaptic 
vesicles and number of vesicles released, was identical in presynaptic terminals of 
each group.  
 
Thus, EPO treatment of autaptic neurons leads to a reduction in the amount of 
primed vesicles or number of synapses without altering efficiency of vesicle fusion 
and vesicle dynamics. Counting of synaptic boutons per neuron revealed a 
considerable increase from day 9 to day 14 in culture, which, however, was not 
changed by EPO (Figure 6h). Therefore, EPO is likely to reduce the number of active 






We show that young mice, systemically treated with EPO for 3 weeks, exhibit 
improved hippocampus-associated memory. This selective improvement was 
maintained for an EPO treatment-free period of another 3 weeks, and was unrelated 
to increases in hematocrit, indicating a hematopoiesis-independent effect of EPO on 
neuroplasticity. The long-lasting effect of EPO on neuroplasticity was confirmed by 
analyses of paired-pulse facilitation, STP, LTP and STD, as well as of spontaneous 
synaptic activity in acute hippocampal slices, obtained from EPO-treated mice at the 
time point of EPO-induced enhancement of memory. MEA recordings of neuronal 
assemblies in vitro and the analysis of individual autaptic hippocampal neurons did 
not only confirm direct effects of EPO on neural cells, but also reveal potential 
mechanisms of action: EPO leads to a reduction in the amount of primed vesicles 
without altering number of synapses or efficiency of vesicle fusion and vesicle 
dynamics. Thus, most likely via increasing the proportion of silent synapses, EPO 
reduces overall spiking activity of neurons and enhances bursting efficiency of 
selected neuronal networks. Most of these data are consistent with EPO shifting the 
balance between excitatory and inhibitory transmission (i.e. functionally silencing a 
subset of excitatory presynaptic sites and increasing activity of inhibitory neurons), 
although other mechanisms cannot be entirely excluded at this point. 
 
In humans, improvement of cognitive function upon treatment with EPO has only 
been demonstrated in disease states [18, 19, 34], i.e. in conditions of 
reduced/disturbed baseline performance. Exploring healthy individuals has therefore 
been a risky endeavour, although, if successful, promised to deliver a cleaner picture 
of mechanisms of EPO action, lacking interference with potential disease variables. 
Similar to what is observed with endurance and muscular performance during doping 




memory effects in healthy mice. EPO-treated compared to placebo-treated mice had 
a significantly longer duration of freezing, as readout of memory function, during a 
contextual memory test that is known to be critically dependent on the hippocampus 
[36, 37]. This finding implies that in healthy individuals the potential cognitive capacity 
is not fully exhausted. Although results were obtained in mice, the work of Miskowiak 
and colleagues [20] may indicate that respective effects can be expected in healthy 
humans.  
 
Similar to the findings of Miskowiak et al. [20], the effect of EPO on hippocampal 
functions was measurable at 1 week after injection. In our setting, treatment for 3 
weeks (11 injections) was necessary to obtain positive results on cognitive 
performance. Reduced to only three injections, no measurable effect on the 
behavioral readout of hippocampal functions was obtained. Healthy humans showed 
increased hippocampal response (perfusion equivalent) in functional magnetic 
resonance imaging upon memory retrieval already 1 week after a single EPO dose. 
However, effects on memory function were also not detectable after this single dose 
[20]. In other words, for cognitive improvement (and not only for increase in 
perfusion), more than a single injection is needed also in humans. In both studies, the 
hematocrit seems irrelevant. In the human study, a single dose of EPO had not 
changed the hematocrit after 1 week [20]. In our study, the hematocrit was already 
back to control levels when we still observed a significant effect on cognition, and 
direct effects of EPO on synaptic plasticity were found in hippocampal cultures. 
 
The persistent effect of EPO on cognition, lasting for over 3 weeks after cessation of 
treatment, indicates alterations in neuroplasticity induced by EPO that do not require 




effects of EPO on motor function, which lasted for up to 6 months after termination of 
a 6-months treatment [19]. In search for a mechanism explaining the lasting influence 
of EPO on hippocampus-associated memory, we detected pronounced EPO effects 
on short-term and long-term plasticity, as well as on excitatory and inhibitory synaptic 
transmission in the Schaffer collateral CA1 pathway. These electrophysiological 
parameters of plasticity have been associated with learning and memory [38-40].  
 
Further exploring mechanisms of action of EPO, we employed multi-electrode arrays 
to study network activity in primary hippocampal cultures. We found that chronic 
application of EPO in a fashion similar to our in vivo approach resulted in persistence 
of a large population of silent channels but enhanced bursting efficiency of discrete 
neuronal circuits. In acute hippocampal slices as well as autaptic hippocampal 
cultures, excitatory synaptic transmission was decreased upon EPO treatment, 
whereas inhibitory synaptic transmission was increased. In line with these data, EPO-
mediated inhibition of glutamate release has been reported for cerebellar granule 
cells [41]. 
 
Together, these findings may point to an enhanced lateral inhibition within the 
hippocampal neuronal network by EPO, leading to amplification of active synaptic 
connections. A concurrent suppression of surrounding synapses by EPO, consistent 
with lasting functional silencing, may ultimately achieve segregation/refinement of 
neuronal networks (for review see [42]). Interestingly, signal transduction pathways 
known to be activated in hippocampal neurons by EPO, include PI3K-PKB/Akt1 and 
RAS-MAPK [43, 44]. Both, the MAPK-mediated pathway [45-47] and PI3K have been 






Although not providing complete mechanistic insight at this point, our data indicate 
that the selective enhancing effect of EPO on hippocampus dependent memory is 
mediated via profound changes in neuroplasticity. These plastic changes, in turn, 
may be based on a more efficient bursting activity of selected synapses together with 
persistent silencing of other synapses.  
 
Methods 
Animals. All experiments were approved by and conducted in accordance with the 
regulations of the local Animal Care and Use Committee. For all experiments, young 
(28 days old) C57/Bl6 male mice were used. They were housed in groups of five in 
standard plastic cages and maintained in a temperature-controlled environment 
(21±2°C) on a 12 h light/dark cycle with food and water available ad libitum.  
 
Drug treatment. For experiments 1-5, mice were injected intra-peritoneal with EPO 
(Epoetin-alpha, Janssen-Cilag, Neuss, Germany, 5 IU/g in 0.01 ml) or placebo 
(diluent for EPO, 0.01 ml/g) every other day for 3 weeks (11 injections in total). Two 
additional groups of mice received only three injections of EPO or placebo either at 
the beginning or at the end of the 3-week treatment period. The remaining eight 
injections were all placebo. Before each injection, the body weight was measured. 
The experimenter, who administered the injections and performed the tests, was 
blinded concerning group assignment.  
 
Experimental design of mouse studies. The experimental design including 




Experiment 1: EPO effects on basic behavior and cognition of young healthy mice 
after termination of EPO treatment were assessed. Mice were tested, starting on the 
day after the last injection, for anxiety (EPM, elevated plus maze), spontaneous loco-
motor activity (OF, open field), exploratory activity (HB, hole board), motor functioning 
(RR, rota-rod) and memory (FC, fear conditioning).  
Experiments 2 and 3: In these experiments, mice were tested in FC either 3 or 4 
weeks after the last EPO injection to explore the duration of EPO effects on 
cognition. Hematocrit was determined immediately after FC.  
Experiments 4 and 5: These experiments were set up to obtain brain tissue of mice 
for neurophysiology and histology at the time point with the most prominent effect of 
EPO on hippocampus dependent memory. 
 
Behavioral testing. Group size in all behavioral experiments amounted to N=15-28. 
Exact numbers of individual experiments are given in the legend of Figure 2.  
Elevated plus maze: The mouse was placed in the central platform, facing an open 
arm of the plus-maze. Behavior was recorded by an overhead video camera and a 
PC equipped with ‘Viewer’ software (Biobserve, Bonn, Germany) to calculate the time 
each animal spends in open or closed arms. The time spent in open arms was used for 
estimation of open arm aversion (fear equivalent).  
Open field: Spontaneous activity in open field was tested in a grey Perspex arena 
(120 cm in diameter, 25 cm high). The mouse was placed in the center and allowed 
to explore the open field for 7 min. The behavior was recorded by a PC-linked 
overhead video camera. ‘Viewer’ software was used to calculate velocity, distance 
traveled and time spent in central, intermediate or peripheral zones of the open field.  
Hole board: The hole board test measures exploratory activity. The apparatus 




transparent floor raised 5 cm above the bottom of the chamber with 12 equally 
spaced holes, 2 cm in diameter. Mice were allowed to explore the chamber for 3 min 
and the number of explored holes (head dips) was scored by a trained experimenter.  
Rota-rod: Rota-rod is a test for motor function, balance and coordination and 
comprises a rotating drum (Ugo Basile, Comerio, Varese, Italy), which is accelerated 
from 4 to 40 revolutions per minute over the course of 5 min. Each mouse was 
placed individually on a drum and the latency of falling from the drum was recorded 
using a stop-watch. To assess motor learning, the rota-rod test was repeated 24 h 
later.  
Cued and contextual fear conditioning: The fear conditioning test was performed 
as described in detail earlier [23]. Briefly, mice were trained within the same session 
for both contextual and cued fear conditioning. Training consisted of exposing mice 
for 120 s to the context to assess the baseline level of activity. This period was 
followed by a 10 s, 5 kHz, 85 dB tone (conditioned stimulus, CS). Immediately after 
the tone, a 2 s, 0.4 mA foot shock (unconditioned stimulus, US) was applied. This 
CS-US pairing was repeated 13 s later. All mice remained in the conditioning 
chambers for an additional 23 s following the second CS–US pairing. The contextual 
memory test was performed 72 h after this training. Mice were monitored over 2 min 
for freezing in the same context as used for training. The cued memory test was 
performed 76 h after training in a new chamber. First, mice were monitored for 
freezing over a 2 min pre-cue period with no tone to assess freezing in the new 
context. Next, a 2 min cue period followed during which the tone was presented. 
Duration of freezing behavior, defined as the absolute lack of movement (excluding 
respiratory movements), was recorded by a video camera and a PC equipped with 





Brain dissection and sections preparation. For RNA and protein analysis, mice 
were deeply anaesthetized and decapitated. Hippocampi were taken out, 
immediately frozen on dry ice and stored at -80˚C. For histology, mice were perfused 
under deep anesthesia with 4% paraformaldehyde. Brains were dissected, postfixed 
overnight at 4˚C and transferred into 30% sucrose/PBS solution. After having sunk, 
they were frozen in liquid nitrogen and stored at -80˚C. Whole mouse brains were cut 
into 30 µm thick coronal sections on a cryostat (Leica, Wetzlar, Germany) and kept in 
a storage solution (25% ethyleneglycol and 25% glycerol in PBS). Every 10th section 
throughout the dorsal part of the hippocampal formation was selected for staining, 
yielding five to six sections per brain, used for either volumetrical analysis or confocal 
microscopy. 
 
Volumetric measurements using histological sections. The sections were 
mounted on Super Frost microscopic slides, washed in phosphate buffer, then 
immersed for 25 min in a dilute cresyl violet stain (0.01%) in acetate buffer (pH 4.5), 
dehydrated in serial dilutions of ethyl alcohol and finally coverslipped using DePeX 
(Serva, Heidelberg, Germany). Calculation of the volume of CA1, CA3 subregions 
and the total hippocampus was based on thickness of the sections and areas 
obtained by tracing contours around the regions of interest, using a light microscope 
(Olympus BX50) modified for stereology with a 10x objective, a computer-driven 
motorized stage, Z-axis position encoder (microcator), and a microfire video camera 
interfaced to a PC with the software Stereo Investigator 6.55 (MicroBrightfield, Inc., 






Confocal analysis. For counting of synaptic boutons, sections were washed in PBS, 
permeabilized and blocked in 5% blocking serum for 1 h at 4˚C, and incubated at 4ºC 
overnight with rabbit polyclonal synapsin1 antibody (1:4000; Synaptic Systems, 
Goettingen, Germany). After PBS washes, the sections were incubated with anti-
rabbit AlexaFluor555-labeled secondary antibody (1:2000; Invitrogen, Karlsruhe, 
Germany). Following PBS washes, sections were mounted on Super Frost 
microscopic slides, air dried and coverslipped with fluorescence mounting medium 
(Vector, Burlingame, CA, USA) containing DAPI. Synapsin1 immunoreactive 
presynaptic boutons were analyzed within stratum radiatum of area CA1 and stratum 
lucidum of area CA3 of hippocampus. Images were obtained at a zoom factor 4 using 
an inverted confocal laser scanning microscope (LSM 510; Zeiss, Goettingen, 
Germany) with a 63x oil-immersion objective. For intensity comparisons, gain and 
offset were held constant across images. Synapsin1 immunoreactive punctae were 
quantified using ImageJ software (Rasband, W.S., ImageJ, U. S. National Institutes 
of Health, Bethesda, Maryland, USA). Images were manually thresholded and 
particle analysis plugin was used to calculate the number of immunoreactive punctae. 
 
Hippocampal slice preparation and solution. Acute hippocampal slices were 
prepared from 56 days old mice (Figure 1, Exp. 4). As in all experiments performed 
here, the experimenter was blinded regarding group assignment. Mice were deeply 
anesthetized with diethyl ether before decapitation. The brain was quickly removed 
and immersed for 2-3 min in ice-cold artificial cerebrospinal fluid (ACSF). The ACSF 
had the following composition (in mM): 130 NaCl, 3.5 KCl, 1 CaCl2, 1.2 MgSO4, 24 
NaHCO3, 1.25 NaH2PO4, 10 Glucose, with the pH adjusted to 7.4. Transverse slices 
of 400 µm thickness were cut with a vibroslicer (752 M, Campden Instruments, 




chamber of the Oslo type and allowed to recover for at least 90 min. The recording 
chamber was continuously perfused with ACSF, aerated with 95% O2 and 5% CO2 
(3-4 ml/min). The temperature was kept at 34ºC. 
 
Extracellular recordings of hippocampal slices. The recording electrodes were 
pulled from thin-walled borosilicate glass capillaries (GC150TF-10, Harvard 
Apparatus, Holliston, MA, USA) using a horizontal Flaming-Brown micropipette puller 
(P-80/PC, Sutter Instrument Co., Novato, CA, USA). They were filled with ACSF. 
Monopolar stimulation electrodes made from bare stainless steel microwire (50 µm 
diameter, AM-Systems) were used for stimulation. The stimuli were generated by 
photoelectric stimulus isolation units (Grass PSIU6) triggered by a stimulator (Grass 
S88). Extracellular field potential recordings were done using a custom-built DC 
amplifier. Data were digitized by a DigiData 1322A (Molecular Devices, Sunnyvale, 
CA, USA). Initial analysis of the data was done in Clampfit 9.0 (Molecular Devices, 
Sunnyvale, CA, USA). To evoke field excitatory postsynaptic potentials (fEPSPs), the 
stimulation electrode was placed in stratum radiatum at CA3/CA1 junction for the 
activation of Schaffer collaterals. The recording electrode was placed in the stratum 
radiatum of the CA1 region. The magnitude of fEPSPs was measured as amplitude 
(baseline to peak) and slope (20-80% level of the falling phase). For input-output 
relationship, fEPSPs were evoked with 0.1 ms stimuli at 0.25 Hz and an average of 
four consecutive responses was taken. fEPSP amplitudes and slopes were plotted 
against the stimulus intensity (10 to 150 µA). Paired-pulse facilitation (PPF) was 
measured at different interstimulus intervals (25, 50, 75, 100, 125, 150, 175 and 200 
ms) as the ratio of the second fEPSP to the first fEPSP. Here also the paired stimuli 
were given at 0.25 Hz and an average of four consecutive responses was taken. To 




min and LTP was induced by three trains separated by 20 s, each train consisting of 
100 Hz stimulation for 1s. The post-train responses were then measured every 20 s 
for 60 min. The magnitude of LTP was measured as the average of responses 
between 50 and 60 min after induction. To study long-term depression (LTD), 
baseline responses were evoked every 15 s for 5 min and LTD was induced by 900 
stimuli delivered at 1Hz. The post-train responses were then measured every 15 s for 
60 min. The magnitude of LTD was measured as the average of responses between 
50 and 60 min after induction. 
Whole-cell patch clamp-recordings. Acute transverse 300 µm hippocampal slices 
were prepared as described above. After preparation, slices were incubated for 30 
min at 34°C, followed by room temperature incubation for more than 1h. All 
recordings were performed in CA1 hippocampal pyramidal neurons. The extracellular 
solution in all experiments was the same as the one used in LTP experiments. The 
pipette solution for all experiments contained (in mM): 140 KCl, 1 CaCl2, 10 EGTA, 2 
MgCl2, 4 Na3ATP, 0.5 Na3GTP, 10 HEPES at pH 7.3. Spontaneous inhibitory PSCs 
were recorded at a Cl-reversal potential of about 0 mV in 10 µM CNQX and 40 µM 
AP5. Spontaneous excitatory PSCs were recorded in the presence of 1 µM 
strychnine and 1 µM bicuculline. Signals with amplitudes of at least two times above 
the background noise were selected. Patches with a serial resistance of >10 MΩ, a 
membrane resistance of <0.2 GΩ, or leak currents of >200 pA were excluded. The 
membrane currents were filtered by a four-pole Bessel filter at a corner frequency of 
2 kHz, and digitized at a sampling rate of 5 kHz using the DigiData 1322A interface 
(Molecular Devices, Sunnyvale, CA). Data acquisition and analysis were done using 
commercially available software: pClamp 9.0 (Molecular Devices, Sunnyvale, CA), 






Primary hippocampal neuronal culture. Mice at embryonic day 17 (E17) were used 
for preparation of hippocampal primary neuronal cell cultures [24, 25] Briefly, after 
complete removal of meninges, hippocampi were dissected in warm HBSS solution 
(Invitrogen, Karlsruhe, Germany), supplemented with penicillin and streptomycin, and 
trypsinized. After mechanical trituration with fire polished Pasteur pipettes, cells were 
plated on poly-D-lysine- and laminin-coated 6-well plates (for Western blotting and 
quantitative RT PCR) or on poly-D-lysine- and laminin-coated MEA dishes (for multi-
electrode array, MEA) or on poly-D-lysine- and laminin-coated glass cover slips in 6-
well plates (for immunocytochemistry) at a density of 200000 cells per well. Neurons 
were cultured in MEM/B27 medium (Invitrogen, Karlsruhe, Germany) supplemented 
with sodium bicarbonate, sodium pyruvate, L-glutamine, penicillin, streptomycin and 
0.6% glucose. Cultures were incubated at 37°C under 7.5% CO2 / 92.5% air and 90% 
humidity. One-third of medium volume was exchanged every 5th day. Contamination 
with glial fibrillary acidic protein positive astrocytes on day 5 in culture was 
consistently less than 7%. For all MEA experiments, EPO or control treatment (0.3 
IU/ml = 10-10 M) was started on day 5 and continued by addition of EPO every other 
day until day 25. Cell cultures were maintained until day 50 for MEA, until day 8, 14, 
or 30 for Western blotting and quantitative RT PCR, until day 10 and 30 for 
immunocytochemistry. 
 
Immunostaining of cultured cells. After 10 or 30 days in culture, cells were washed 
in PBS, fixed with 4% paraformaldehyde in PBS, permeabilized and blocked in 0.2% 
Triton X-100/PBS with 10% blocking serum, and incubated at 4ºC overnight with 
mouse monoclonal MAP-2 (1:500; Chemicon, Hampshire, UK) or mouse monoclonal 




blocking serum/PBS. After PBS washes, the cells were incubated with Cy2-labeled 
secondary antibody (1:250; Jackson ImmunoResearch, Newmarket, UK), washed in 
PBS, air dried and coverslipped with fluorescence mounting medium (Vector, 
Burlingame, CA, USA) containing propidium iodide. 
 
Multi-electrode array recordings and analysis. For determination of spontaneous 
electrical network activity in primary mouse hippocampal neuronal cultures, we used 
multi-electrode arrays (MEA) of 60 titanium nitride electrodes with 30 µm diameter 
each and 200 µm inter-electrode distance (Multi Channel Systems, Germany). Raw 
data from the MEA electrodes were amplified by MEA 1060 filter amplifiers 
(bandwidth 3 Hz-10 kHz; gain x 1100). Sampling frequency amounted to 25 kHz. The 
experiments were performed at 37˚C, using a TC01 temperature controller. 
Recording of spontaneous network activity was carried out daily in the morning for 2 
min, starting on day 14 and ending on day 50. This gave us five weeks of daily 
recordings, from week 3 until week 7 (total of 37 days). The choice of morning hours 
for measurements did not affect the statistics, as confirmed by an additional evening 
experiment showing little daily differences. Seven independent “sister” cultures (i.e. 
cultures derived from the same brain preparation), treated with EPO or control were 
analysed. Spike extraction from the continuous data is commonly achieved by spike 
sorting [26, 27]. Having to process 481 2 min recordings, manual interaction, often 
used to improve sorting behavior, was not feasible. Thus, automated spike extraction 
using MEATools, a MATLAB-based toolbox for comprehensive analysis of multi-
neuronal data (http://www.brainworks.uni-freiburg.de/projects/mea/meatools/ 
overview.htm) was employed. For each channel, principal components were 
calculated, and spikes were identified via thresholds in the principal component 




modifications by EPO in the cell cultures, single sample analyses were performed 
first (see Additional file 1). Due to a relatively high background noise and a low 
overall number of spikes in the channels, standard statistics, such as spike rates and 
spike time interval distributions, did not capture significant differences in EPO versus 
control cultures (see Additional files 2 and 3). A direct quantification of the variations 
in bursting and silent channels was therefore necessary. Similar clustering effects 
have been previously studied in oscillator networks on a theoretical level [28, 29]. 
Here, two indices were calculated: (1) In order to measure silencing in the groups, we 
determined the number of channels c
i
(t)  of dish i at time t with basically no spikes 
(less than five spikes per 2 min). We then took the mean of c
i
(t)  over each week and 
compared the time evolution of this mean channel activity using a Wilcoxon rank sum 
test in each week. The test was performed on the samples after outlier removal, 
where an outlier was defined as a sample not lying within 1.5 times the interquartile 
range from the median. (2) In addition to silencing effects, we analysed bursting 
behavior. For this, we calculated the coefficient of variation (CV) of the spike-time 
interval distribution in each channel, i.e. the ratio of standard deviation and mean. 
This measure of dispersion is larger than 1 for hyper-exponential distributions and 
lower than 1 for lower-variance distributions. In the case of bursting channels, over-
proportionally many small spike-time intervals were observed, so the spike-time 
intervals obeyed a hyper-exponential distribution, which could be identified by high 
CV-values of the corresponding channels. We defined bursting behavior if the CV-
value was above 1, and strongly bursting behavior if it was above a threshold of 2.6 
(see also Additional file 1). In order to quantify bursting over all channels, we counted 
the percentage b
i
(t)  of strongly bursting channels of all active channels of dish i at 
time t. By calculating relative bursting with respect to active channels, we were able 




mean over each week, and tested for differing medians of the EPO and the control 
group using a rank sum test.  
 
Autaptic neuron experiments.  
Cell culture: Microislands of astrocyte feeder cells were prepared two days before 
plating hippocampal neurons [30]. Islands of substrate (10 mM acetic acid, 0.1 mg/ml 
poly-D-lysine, and 0.2 mg/ml collagen) were applied to agarose-coated glass 
coverslips using a stamp containing regularly spaced squares (200 µm x 200 µm). To 
obtain astrocytes and hippocampal neurons, P0 mice were decapitated, and brains 
were removed and cleaned of meninges and vascular tissue. To obtain hippocampal 
neurons, hippocampi were removed in HBSS, digested in papain (25 IU/ml, 
Worthington Biomedical) in DMEM (supplemented with 1 mM CaCl2, 0.5 mM EDTA, 
and 1.65 mM L-cysteine) for 45 min at 37°C, incubated for 15 min at 37°C in serum-
free medium (Neurobasal medium A supplemented with 2.5 mg/ml Albumin and 2.5 
mg/ml Trypsin inhibitor) and dissociated. To obtain astrocytes, the cortices of 
separate animals were removed in HBSS, similarly dissociated (digested for 15 min 
at 37°C in Trypsin/EDTA) and plated at a density of 2500 per cm2 in DMEM 
containing 10% fetal calf serum, penicillin/streptomycin, and MITO (Becton 
Dickinson). Before plating the dissociated hippocampal neurons at a density of 300 
per cm2, the medium of the astrocyte feeder cells was replaced with Neurobasal 
medium A (supplemented with B27, Glutamax-I and penicillin/streptomycin). Neurons 
were allowed to mature until days 9, 11, or 14 to be used for electrophysiology or 
immunocytochemistry. Only islands containing single neurons were examined. EPO 
versus control (diluent solution) treatment was performed on day 7. If not otherwise 




Immunostaining: For estimating the number of synaptic boutons in autaptic 
neurons, cells were washed in PBS, fixed with 4% paraformaldehyde in PBS, 
permeabilized and blocked in 0.2% Triton X-100/PBS with 10% blocking serum, and 
incubated at 4ºC overnight with mouse monoclonal synapsin1 antibody (1:1000 
SynapticSystems, Goettingen, Germany) diluted in 1% blocking serum/PBS. After 
PBS washes, cells were incubated with Cy3-labeled secondary antibody (1:1000; 
Jackson ImmunoResearch, Newmarket, UK), washed in PBS and incubated at 4ºC 
overnight with mouse monoclonal MAP-2 (1:500; Chemicon, Hampshire, USA) 
antibody. Following PBS washes, the cells were incubated with Cy2-labeled 
secondary antibody (1:250; Jackson ImmunoResearch, Newmarket, UK), washed in 
PBS, air dried and coverslipped with fluorescence mounting medium (Vector, 
Burlingame, CA, USA) containing DAPI. Images of individual neurons were captured 
using an upright epifluorescence Olympus BX61 microscope (Hamburg, Germany) 
with a 40x oil-immersion objective. Images were photomerged to reconstruct 
individual neurons using Adobe Photoshop CS3 software. The number of synapsin1 
immunoreactive punctae of 18-20 neurons per coverslip (six coverslips per condition) 
were quantified using ImageJ software with manual thresholding and particle analysis 
plugin. Estimation of the percentage of excitatory and inhibitory neurons was 
performed by visual distinction between the degree of arborization, thickness of 
processes and shape of soma. Amount of inhibitory neurons among the total 
neuronal population was found to be 10-20% per culture.  
Electrophysiology: Cells were whole-cell voltage clamped at –70 mV with 
pClamp10 amplifier. All analyses were performed using Axograph 4.9 (Molecular 
Devices, Sunnyvale, CA, USA). The size of the readily releasable pool (RRP) of 
synaptic vesicles was determined by a 6 s application of the external saline solution 




performed in the presence of 300nM tetrodotoxin (TTX). EPSCs were evoked by 
depolarizing the cell from -70 to 0 mV for 2 ms. The effect of high-frequency 
stimulation on the amplitude of EPSCs was measured by applying depolarisations at 
a frequency of 10 Hz for 50 stimuli. To measure NMDA/AMPA ratio, EPSCs were 
stimulated in the presence of 10 mM glycine, 2.5 mM Ca2+ (no Mg2+) to activate the 
synaptic NMDA receptors in hippocampal autaptic culture. The evoked EPSCs had a 
fast AMPA component followed by a slow NMDA component. To examine the 
changes in synaptic NMDA/AMPA ratios in presence and absence of EPO, the 
NMDA components relative to the AMPA component were measured. 
 
Patch-pipette solutions contained (mM): 146 potassium gluconate, 18 HEPES, 1 
EGTA, 4.6 MgCl2, 4 NaATP, 0.3 Na2GTP, 15 creatine phosphate and 5 U/ml 
phosphocreatine kinase (315-320 mOsmol/l, pH 7.3). The extracellular saline solution 
contained (mM): 140 NaCl, 2.4 KCl, 10 HEPES, 10 glucose, 4 CaCl2 and 4 MgCl2 
(320 mOsmol/l, pH 7.3). All chemicals, except for TTX (Tocris Cookson) and 
calcimycin (Calbiochem) were purchased from Sigma. All solutions were applied 
using a fast-flow system (Warner Instruments, Hamden, CT, USA) with custom made 
flow pipes.  
 
Protein extraction and immunoblot analysis. Tissue samples or cells were lysed 
with lysis buffer [50 mM Tris HCL (pH 8.3), 150 mM NaCl, 40 mM NaF, 5 mM EDTA, 
5 mM EGTA, 1 mM Na3VO4, 1% Igepal, 0.1% Natriumdesoxycholat, 0.1% SDS] 
containing 1 mM Phenylmethysulfonylfluoride, 10 µg/ml Aprotinin and 1 mg/ml 
Leupeptin. The lysates were freeze-thawed four times and homogenized by pulling 
through a 1 ml syringe 10 times, transferred into microcentrifuge tubes and 




volumes of Laemmli buffer [250 mM Tris HCL (pH 8.3), 8% SDS, 40% glycerol, 20% 
2-mercaptoethanol, 0.04% pyronin Y], boiled for 5 min at 95˚C and frozen at -20˚C 
until blotting. The protein samples were run on NuPAGE 4-12% Bis-Tris Gel 
(Invitrogen, Karlsruhe, Germany) for three 5 min periods at 200 V and transferred to 
a nitrocellulose membrane. The blots were blocked with 2% ECL Advance blocking 
agent (Amersham, Freiburg, Germany) in Tween 20-Tris-buffered saline (TTBS) at 
room temperature for 1 h and incubated at 4ºC overnight with primary antibody for 
synapsin1 (1:10000; Synaptic Systems, Goettingen, Germany) or synaptophysin 
(1:500; Sigma, Germany) or α-tubulin as an internal control (1:5000; Sigma, 
Germany). Immunoreactive bands were visualized by using secondary antibodies 
coupled to horseradish peroxidase by enhanced chemoluminescence (Amersham, 
Freiburg, Germany). Densitometric analysis of the protein bands was performed by 
using ImageJ software.  
 
RNA isolation and expression analysis by quantitative real-time RT-PCR. RNA 
was isolated from tissue samples or cells by using the RNeasyPlus kit (Qiagen, 
Hilden, Germany). First strand cDNA was generated from total RNA using N9 random 
and Oligo(dT)18 primers. The relative concentrations of mRNAs of interest in different 
cDNA samples were measured out of four replicates using the threshold cycle 
method (Ct) for each dilution and were normalized to levels of murine 18S RNA. 
Reactions were performed using SYBR green PCR master mix (ABgene, Foster City, 
CA, USA) according to the protocol of the manufacturer. Cycling was done for 2 min 
at 50°C, followed by denaturation at 95°C for 10 min. The amplification was carried 
out by 45 cycles of 95°C for 15 s and 60°C for 60 s. The specificity of each primer 
pair was controlled with a melting curve analysis. Quantitative RT-PCR was 




NM_007540.3 Mus musculus brain derived neurotrophic factor (BDNF), mRNA 
mouse BDNF fwd: GCA TCT GTT GGG GAG ACA AG 
mouse BDNF rev: TGG TCA TCA CTC TTC TCA CCT G 
NM_010149.2 Mus musculus erythropoietin receptor (EPOR), mRNA 
mouse EPOR fwd: CCT CAT CTC GTT GTT GCT GA 
mouse EPOR rev: CAG GCC AGA TCT TCT GCT G 
NM_009305.1 Mus musculus synaptophysin (Syp), mRNA 
mouse synaptophysin fwd: CAA GGC TAC GGC CAA CAG 
mouse synaptophysin rev: GGT CTT CGT GGG CTT CAC T 
NM_013680.3 Mus musculus synapsin1 (Syn1), mRNA 
mouse synapsin1 fwd: GGA AGG GAT CAC ATT ATT GAG G 
mouse synapsin1 rev: TGC TTG TCT TCA TCC TGG TG 
 
Statistical analysis. Statistical significance was evaluated using two-tailed unpaired 
Student´s t-test, with or without Welch’s correction, depending on the distribution of 
the data (tested with a Kolmogorov-Smirnov test). Significance level was set to 
P<0.05. Numerical values are represented as mean±S.E.M. in Figures and text. 
Plotting of the data as well as statistical analyses were done in Prism 4 (GraphPad 
Software, San Diego, CA, USA) and MATLAB 7 (The MathWorks, Natick, MA, USA).  
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Figure 1  
Experimental design of the in vivo studies. The time line of behavioral testing and 
brain dissection is presented. EPO or placebo was injected every other day for 3 
weeks (11 injections in total). Tests performed were elevated plus maze (EPM), open 
field (OF), hole board (HB), rota-rod (RR), and fear conditioning (FC), including 
training and testing 72 h later.  
 
Figure 2 
Effects of EPO on hippocampus dependent memory. Percentage of freezing as a 
readout of memory function in fear conditioning shows significant effects upon EPO 
treatment in the contextual memory (context) task at 1 week (a) and 3 weeks (b), but 
no longer at 4 weeks (c) after the last EPO injection. Percentage of freezing 
measured during training (baseline), exposition to the new context (pre-cue), and 
testing for cued memory (cue) is not different between the groups. No differences are 
seen in EPM (d), OF (e), HB (f), and RR (g). Mean±S.E.M. N=28 for experiment in 
(a) and N=14 for all other experiments (b-g).  
 
Figure 3 
Neurophysiology of acute hippocampal slices: Extracellular recordings. (a-b) 
Input-output relation is not altered at Schaffer collateral-CA1 synapses in EPO-
treated mice. (a) Sample recordings at 50% of maximal response (average of four 
traces) are shown for control and EPO-treated mice. (b) Input-output curve as a 
measure of baseline excitatory synaptic transmission: fEPSP slope, plotted against 




(P=0.3094). Inset: Half maximal stimulation strengths are not significantly different. 
(c-d) Paired-pulse facilitation is enhanced in EPO-treated mice. (c) Sample traces 
are presented. (d) Paired-pulse ratio (fEPSP slope for the second stimulus/fEPSP 
slope for the first stimulus) at inter-stimulus intervals of 25-150 ms is significantly 
greater in EPO-treated mice. (e-h) Increased LTP at Schaffer collateral CA1 
synapses in EPO-treated mice. (e) Sample traces of responses are shown before 
and after high frequency stimulation (HFS; 3 x 100 Hz for 1 s each, 20 s interval). (f) 
Long-term potentiation elicited by HFS: Slopes of fEPSP are normalized to baseline 
and plotted against time. Time-point 0 represents application of HFS. (g) Magnitude 
of STP, determined as maximal responses within 1 min after HFS, is significantly 
greater in EPO-treated mice. (h) Magnitude of LTP, determined as responses 
between 50 and 60 min after HFS, is significantly greater in EPO-treated mice. (i-l) 
Increased STD at Schaffer collateral-CA1 synapses in EPO-treated mice. (i) Sample 
traces of responses are shown before and after low frequency stimulation (LFS; 1 Hz 
for 900 stimulations). (j) Long-term depression elicited by LFS: Slopes of fEPSP are 
normalized to baseline and plotted against time. Time 0 represents application of 
LFS. (k) Magnitude of STD, determined as maximal responses within 1 min after 
LFS, is significantly greater in EPO-treated mice. (l) Magnitude of LTD, determined 
as responses between 50 and 60 min after LFS, is not significantly changed in EPO-
treated mice (P=0.0869).  
 
Figure 4 
Neurophysiology of acute hippocampal slices: Intracellular recordings.  (a-c) 
EPO enhances inhibitory transmission. (a) Representative recordings of 
spontaneous, pharmacologically isolated inhibitory postsynaptic currents 




altered in EPO-treated mice (N=6 neurons / 5 mice) compared to control (N=4 
neurons / 4 mice; P=0.0869). (c) Averaged frequency of sIPSCs is significantly 
enhanced in EPO-treated mice (N=6 neurons / 5 mice) compared to control (N=4 
neurons / 4 mice). (d-f) EPO decreases excitatory transmission. (d) Representative 
recordings of spontaneous, pharmacologically isolated excitatory postsynaptic 
currents (sEPSCs) from CA1 neurons. (e) Averaged amplitude of sEPSCs is 
significantly decreased in EPO-treated mice (N=4 neurons / 4 mice) compared to 
control (N=4 neurons / 3 mice). (f) averaged frequency of sEPSCs is significantly 
decreased in EPO-treated mice (N=4 neurons / 4 mice) compared to control (N=4 
neurons / 3 mice).   
 
Figure 5 
Multi-electrode array studies of primary hippocampal neurons. (a-b) 
Characterization of the cultures. (a) Immunocytochemical staining demonstrates 
maturation of cellular networks from day 10 to day 30. Propidium iodide staining of all 
nuclei (red), visualization of cell types by MAP-2 (mature neurons) or GFAP 
(astrocytes) staining (green), as well as merged pictures are presented (scale 
bar=100 µm). (b) Cellular composition of networks remains stable over time and is 
not altered by EPO treatment (0.3 IU/ml every other day) from day 5 through 25 in 
culture (Mean±S.E.M. of N=3 independent cultures per time point). (c) Demonstration 
of primary hippocampal neurons grown on multi-electrode array dishes, containing 60 
electrodes/dish. (d-e) Spontaneous electrical activity of primary hippocampal 
neuronal networks in culture is measured daily from week 3 through week 7. Group 
statistics of the multi-electrode array recordings over each week show significant 
dissociation over time of EPO versus control cultures. (d) Silencing group statistics 




be observed in EPO-treated cultures. (e) Bursting group statistics show that the 
percentage of strongly bursting channels increases in the EPO group after 
termination of treatment. Medians±S.E.M. presented of N=7 independent cultures. P 
values are given in the text. 
 
Figure 6  
Autaptic hippocampal neuronal cultures. (a-g) Whole-cell electrophysiological 
recordings from single hippocampal neurons treated with either EPO (0.3 IU/ml) or 
control (diluent only) on day 7 and measured from day 9-14. Results indicate a 
reduction in the amount of primed vesicles without altering efficiency of vesicle fusion 
and vesicle dynamics. Mean±S.E.M. presented. N=40-60. (h) Analysing the number 
of synaptic boutons upon immunocytochemical staining for synapsin1 revealed an 
almost identical increase of boutons over time in EPO-treated and control neurons. 
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4. Molecular determinants underlying rapid cycling 
disorder and new treatment approaches 
 
4.1 Overview of project II 
Rapid cycling syndrome is a rare disease affecting 10-30 % of patients with 
bipolar disorder. According to the DSM-IV (Diagnostic and Statistical Manual of 
Mental Disorders) criteria, a patient can be diagnosed with the rapid cycling 
syndrome if he/she experiences at least four episodes of major depression, 
mania, mixed mania, or hypomania in the past year, occurring in any combination 
or order. The patient should experience a complete manic or a complete 
depressive episode occurring after one another for at least 1 week. These 
patients are poor responders to mood stabilizers and currently, no other 
treatments are available. Moreover, mechanisms underlying bipolar affective 
disorders and their subgroup rapid cycling syndrome are still unkown. 
 
In this original publication, we studied a rapid cycling patient with a 16 year-old 
disease history. In order to find out the genes that are differentially expressed in 
manic and depressed episodes that would help us to get closer to understand  
the genetic mechanisms leading to the switch between different disease 
episodes, we exploited RNA isolated at different disease stages from peripheral 
blood mononuclear cells (PBMC) of the patient. Two recent publications have 
reported changes in gene expression profiles using microarray analysis on post 
mortem brain tissue of bipolar patients (Nakatani et al., 2006; Ryan et al., 2006). 
However, these studies failed to report a single overlapping gene. Keeping in 
mind the difficulties and challenges arising from postmortem studies, we 
performed the microarray analysis in a living patient. Since bipolar disorder is a 
systemic disease, we believe that changes obtained from periphery would as well 
give us a hint about the cycling changes occurring in the brain. Moreover, global 
gene expression analysis using PBMC to identify molecular signatures of the 
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disease pathology has proven to be useful in different brain diseases (Achiron 
and Gurevich, 2006; Buttarelli et al., 2006; Grond-Ginsbach et al., 2008). 
 
In order to identify genes regulated differentially in manic and depressed phases, 
we used a three-tiered strategy. First, blood was collected from the patient on 
two consecutive days at a specific time in the morning (8:00 a.m.). Blood 
samples were collected when the patient was in the middle of her two 
consecutive manic or depressed episodes. We performed microarray analysis on 
RNA isolated from PBMC of the patient which was followed by a two-step 
bioinformatic processing. In this way, we excluded genes that showed different 
expression levels between two consecutive days of a certain episode as well as 
genes that were differentially expressed between two manic or two depressed 
episodes. Therefore, we could exclude genes that showed daily and monthly 
variations using this three-tiered experimental strategy. Next, we validated the 
results of the microchip screening by performing qRT-PCRs and selected the 
genes that showed the same expression pattern in microarray analysis. We 
further confirmed the results of qRT-PCRs with additional blood samples 
collected more than one year later.  
 
After comparing the expression pattern of the remaining genes between the 
different episodes, we grouped these genes according to the biological 
categories. After this careful screening approach, we were left with eight different 
genes that were involved in prostaglandin metabolism, PTGDS (lipocalin-type 
prostaglandin D synthetase) and AKR1C3 (prostaglandin D2 11-ketoreductase), 
neurodevelopment, NRG1 (neuregulin 1) and SPON2 (spondin 2), regulation of 
the immune system, GZMA (granzyme A) and KLRD1 (killer cell lectin-like 
receptor subfamily D, member1/CD94), as well as hemoglobins A and B (HBA 
and HBB).  
 
The most striking finding was the association of two prostaglandin genes, 
PTGDS and AKR1C3, with rapid cycling disorder. Both genes showed higher 
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expression in depressed episodes compared to manic episodes. PTGDS 
catalyzes conversion of PGD2 from PGH2 (the product of oxygenation of 
arachidonic acid by cyclooxygenases) and is preferentially expressed in CNS 
where it is involved in various functions including sleep, pain and odor 
responses, may serve an anti-apoptotic role for oligodendrocytes (Taniike et al., 
2002) and was shown to be induced upon pathological conditions (Kagitani-
Shimono et al., 2006; Kawashima et al., 2001; Mohri et al., 2006; Taniguchi et 
al., 2007). AKR1C3 is also involved in prostaglandin synthesis by catalyzing 
conversion of PGF2α from PGD2. Prostaglandin synthesis has been shown to be 
involved in homeostasis, regulation of sleep, allergic responses and inflammation 
(O'Hara et al., 1999; Qu et al., 2006). Interestingly, altered prostaglandin 
metabolism has been reported in major affective disorders (Calabrese and 
Gulledge, 1984; Lowinger, 1989) and altered levels of prostaglandins have been 
implicated to cause mood disorders (Bishop et al., 1987; Lloyd, 1992). Moreover, 
prostaglandins, especially PTGDS, have important roles in hibernation cycle of 
mammals. Hibernation cycle is accompanied with dramatic physiological 
changes including periodic eating, sleeping and high psychomotor activity. Based 
on association of prostaglandins with hibernation and keeping in mind that the 
hibernation involves periodic and alternating behavior, we have developed the 
hibernation hypothesis of rapid cycling which might reflect an evolutionary 
ancient behavioral program in humans and become reactivated under 
pathological conditions.  
 
In order to investigate the relevance of our findings in differential prostaglandin 
gene expression, we started a clinical experiment in which we offered the patient 
a treatment approach using cyclooxygenase-2 (COX2) inhibitor, celecoxib. 
Interestingly, celecoxib has previously been used in clinical trials on patients with 
major monopolar depression (Muller et al., 2006) and bipolar depression (Nery et 
al., 2008) both of which showed promising results. Moreover, increased 
prostaglandin E2 (PGE2) and COX2 production in schizophrenic and depressive 
patients has been discussed in a recent review which suggests inhibitors of this 
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enzyme to be used in clinical studies involving patients of the respective 
diseases (Muller and Schwarz, 2008). COX2 treatment on our patient, with a 
daily dose of 400mg, was continued for about 5 months and was well tolerated. 
Before and during treatment period, we performed psychopathology ratings on 
the patient to follow the disease course. Celecoxib treatment led to a significant 
reduction in overall manic and depressed rating scores over five months. The 
positive effect of celecoxib on our patient, who previously had been treated with 
many other drugs and had never benefited from any, made us emphasize the 
role of the prostaglandin metabolism in rapid cycling disorder and offer this new 
























4.2 Original publication 
Begemann M*, Sargin D*, Rossner MJ, Bartels C, Theis F, Wichert SP, Stender 
N, Fischer B, Sperling S, Stawicki S, Wiedl A, Falkai P, Nave KA, Ehrenreich H. 
(2008). Episode-specific differential gene expression of peripheral blood 
mononuclear cells in rapid cycling supports novel treatment approaches. 
Molecular Medicine 14 (9-10): 546-552 
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Personal contribution: 
I was involved in the design and concept of the experimental work, interpretation 
of the results, validating the work in the context of the existing literature (creating 
a literature data base), as well as preparation of the manuscript. I also performed 
microarray analysis and interpretation; choosing the genes interesting for 
biomedical analysis; primer design and testing for qRT-PCR. I confirmed the 
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INTRODUCTION
Rapid cycling syndrome is a bipolar af-
fective disorder, amounting to 10% to 30%
of the bipolar population. It is character-
ized by at least four episodes per year and
rapid shifts between cycles. Patients with
bipolar affective disorder, as well as pa-
tients with rapid cycling syndrome, typi-
cally experience their first major mood
episode during adolescence (1–5).
Recently, gene expression data from post
mortem brains of bipolar patients were
compared with those of healthy controls in
two independent studies (6,7). While post
mortem approaches certainly cannot reveal
cyclic changes of gene expression, these
studies also failed to yield a single overlap-
ping candidate gene for bipolar disease.
Moreover, the lack of an adequate animal
model for bipolar disorder demands novel
experimental approaches.
We hypothesized that cycling alter-
ations of brain functions in bipolar dis-
ease are reflected by systemic physiologi-
cal changes that have a molecular genetic
basis. If true, it should be possible to ob-
tain molecular signatures of manic and
depressed states even outside the brain,
such as in peripheral blood mononuclear
cells (PBMC). While not disease causing,
such gene expression changes in PBMC
may shed light on similar cyclic alter-
ations in brain.
To study quantitative peripheral gene
expression, we specifically refrained
from comparing larger groups of bipolar
patients (who are genetically heteroge-
neous and differ in baseline gene expres-
sion profiles), and aimed instead at
monitoring the gene expression in one
individual, serving always as her own
control, at recurrent stages of the disease.
CASE REPORT
The female patient, born in 1945, had
no prior medical illness and no evidence
of neuropsychiatric illnesses in her family.
In 1991, she became ill with rapid cycling
syndrome and kept a diary over her ill-
ness, used to reconstruct 108 cycles over a
16-year period. The time series suggests
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complex rhythms in periodicity with
mean total cycle lengths of 53 ± 21 d,
switching within hours between manic
(mean 28 ± 14 d) and depressed (mean 
26 ± 14 d) episodes without normal inter-
vals (Supplementary Figure 1). Results of
affective rating scales obtained repeatedly
during depressed and manic episodes,
together with psychopathology, neu-
ropsychological test results, appearance,
autonomic, and physical signs are sum-
marized in Table 1.
In addition to typical affective symp-
toms, the patient has physical and
cognitive signs recurring in an episode-
specific manner. In the first 2 to 3 d of a
manic episode, she is sleepless and
restless; in the following d, she sleeps 3
to 4 h per night. The 2 to 3 d before the
end of manic episodes, she notes a 
‘normalization of sleep’ with non-
interrupted sleep of regular 8 h duration.
The patient eats and drinks excessively
during manic episodes, leading to alter-
nating weight changes (up to 5 kg) be-
tween episodes and hyperhydration,
resulting in significant shifts of hemato-
crit and hemoglobin concentrations.
Three d after the onset of manic epi-
sodes, the patient regularly develops
Table 1. Psychopathology, physical signs and neuropsychological test results (before celecoxib).
Category Depressed episode Manic episode
Psychopathology
Mood dysphoric, despair, anxiety expansive, exuberant, irritable
Drive impaired: increased:
- most of the time in bed - seeking contacts
- social withdrawal - loss of inhibition
- neglected personal hygiene - unnecessary purchases
- reduced self-care - booking of travels
Thought process brooding, difficulty making decisions, slowed logorrhea, distractibility, poor concentration,
thinking racing thoughts
Suicidality passive death wishes joie de vivre (“Lebensfreude”)
Gestures and mimic mask-like face and slow limb movements rich in gestures and facial expression
oculomotoric decreased oculomotoric increased
sad appearing searching for eye contact and attention
withdrawn
Voice low pitched, monotonous high pitched, melodious
Handwriting jittery and slow orthographic mistakes and corrections
Dotting moderately impaired normal
Tapping moderately impaired moderately impaired
HAM-Da range between 31 and 38 range between 3 and 4
BDIb range between 44 and 52 range between 3 and 5
YMRSc range between 1 and 3 range between 21 and 24
PANSSd range between 84 and 92 range between 40 and 41
Autonomic and physical signs





Allergy no allergies susceptibility to allergies
Edema no edema edema on lower extremities
Neuropsychology
Short-term memory mildly impaired mildly impaired
Long-term memory normal normal
Working memory moderately impaired severely impaired
Semantic fluency moderately impaired normal
Executive functions moderately impaired severely impaired
Psychomotor speed moderately impaired moderately impaired
aHamilton Depression Rating Scale.
bBeck Depression Inventory.
cYoung Mania Rating Scale.
dPositive and Negative Syndrome Scale.
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edema in her lower extremities that re-
cover immediately after onset of depres-
sion. Only during manic episodes does
she become susceptible to seasonal aller-
gies (hay fever). This allergic response
is rarely observed during depressed epi-
sodes. Witnesses describe a change of
her voice in the last 2 to 3 d of manic
episodes to raspy and less melodious.
At the end of depressed episodes, her
voice becomes more cheerful and richer
in tonal inflections. The patient is not
aware of these changes. Because there
was an episode-specific susceptibility
to allergens, lymphocyte subpopula-
tions were studied by fluorescence-
activated cell sorting in different epi-
sodes. Subtle shifts between CD4-helper
and CD8-suppressor cells were noted
(Supplementary Figure 2).
The cyclic pattern of the patient’s af-
fective disorder has had a poor response
to pharmacologic treatment over the past
16 years, such as lithium, venlafaxine,
chlorprothixene, citalopram, paroxetine,
carbamazepine, valproic acid, trim-
ipramine, lamotrigine, olanzapine, or
flupentixol, and no response to psy-
chotherapy and hypnosis. Antipsychotic
medication, such as flupentixol, some-
what reduced the severity of symptoms
but not the cyclic behavior of the disor-
der. During the time of all analyses pre-
sented here, the patient was on continu-
ous lamotrigine medication (400 mg),
resulting in comparable serum levels of
4.1–8.9 μg/mL upon repeated controls
(therapeutic range: 2-10 μg/mL). No
other medication was allowed 2 wks be-
fore or during the time of each testing, or
before and during the treatment ap-
proach, reported here, using the cy-
clooxygenase inhibitor celecoxib (Cele-
brex, Pfizer, Karlsruhe, Germany, 2 × 200
mg daily per os).
MATERIALS AND METHODS
Strategy of Episode-Dependent Gene
Shift Detection
A three-tiered approach was used to
identify candidate genes that are ex-
pressed in an episode-specific fashion.
In the first step, eight blood samples for
PBMC isolation (see below) were col-
lected (always at 8:00 a.m. after
overnight fasting conditions) in the ap-
proximate middle of two different con-
secutive depressed and manic episodes
on two consecutive days each. All sam-
ple collection was done well outside the
hay fever season and in complete ab-
sence of allergic symptoms. The screen-
ing identified genes that showed at least
two-fold differences in expression in
manic compared with depressed epi-
sodes, and vice versa. After screening by
microarrays, the data set was submitted
to two bioinformatic processing steps
(see below). The data were normalized
and analyzed to identify and exclude
genes that differed between the two
consecutive days within a particular
episode (arbitrary daily variation). Fur-
ther genes were excluded that were dif-
ferentially expressed within the two de-
pressed or within the two manic
episodes (arbitrary monthly variation).
The expression pattern of the remaining
depressed and manic episode genes was
subsequently compared. Using this ap-
proach, several genes were identified
that showed high expression in de-
pressed and low in manic episodes, and
vice versa. Because the patient never had
periods where she was free of symp-
toms, samples could not be obtained
within an euthymic episode.
Isolation of Peripheral Blood
Mononuclear Cells (PBMC)
PBMC were collected applying the
standard Ficoll-Paque Plus isolation pro-
cedure (Amersham Biosciences, Freiburg,
Germany). RNA was prepared using
Trizol and Qiagen RNAeasy columns
(Qiagen, Hilden, Germany). The RNA




Transcriptome analysis was per-
formed using the GeneChip Human Ge-
nome U133 Plus 2.0 (Affymetrix, Santa
Clara, CA, USA) (8) according to the
published protocols (9). All cDNAs
used for microarrays were one-round
amplified. GeneChip data were ana-
lyzed using the software GCOS version
1.2 (Affymetrix). Detailed data analysis
was performed with R open-source





Genes found to be differentially regu-
lated by DNA microarray analysis were
subsequently validated independently
using qRT-PCR. Cyclic changes in the ex-
pression of these genes were confirmed
further on PBMC of additional blood
samples obtained up to two years after
the initial screen. qRT-PCR was per-
formed with the aid of SYBR Green de-
tection on Applied Biosystems 7500 Fast
System. CT (cycle threshold) values were
standardized to CT values of GAPDH.
Primers are listed in Supplementary
Table 1.
Statistical Analyses
All numerical results are presented as
mean ± SD in the text and mean ± SEM in
the Figures. Statistical analyses (10,11) and
Fast Fourier Transformations (12) were
performed as published using MATLAB
R2007a software. Nonparametric indepen-
dent Mann-Whitney U test (two-tailed)
and Student t test (two-tailed) were calcu-
lated using SPSS 16.0 for Windows.
All supplementary materials are available
online at molmed.org.
RESULTS
A three-tiered approach was employed
to identify genes that were regulated in an
episode-specific fashion (Figure 1A). We
grouped the genes in biological categories
and present their mean expression pattern
over six to ten separate time points during
either depression or mania (Figure 1B–1E).
Notably, the genes involved in
prostaglandin metabolism, PTGDS
(lipocalin-type prostaglandin D syn-
thetase), and AKR1C3 (prostaglandin D2
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11-ketoreductase), showed higher expres-
sion in depressed episodes (Figure 1B).
We also identified two neurodevelop-
mental genes that revealed opposing
gene expression: NRG1 (neuregulin-1)
was expressed higher in manic, SPON2
(spondin-2) in depressed episodes (Fig-
ure 1C). Several other genes, involved in
regulation of the immune system, were
episode-specifically expressed. These in-
clude GZMA (granzyme A) and KLRD1
(killer cell lectin-like receptor subfamily D,
member 1/CD94) with higher expression
in depressed as compared with manic
episodes (Figure 1D). Hemoglobin genes
A and B (HBB and HBA) were higher in
manic, compared with depressed epi-
sodes. This contrasts the hemoglobin
(protein) concentration in whole blood
(insert) showing opposite regulation
(Figure 1E).
As discussed below, the most intriguing
finding was the association of prostaglandin-
synthesizing genes PTGDS (lipocalin-type
prostaglandin D synthetase) and AKR1C3
(prostaglandin D2 11-ketoreductase) with
rapid cycling. We undertook a clinical ex-
periment to explore the relevance of this
observation and to distinguish between a
disease marker and mediator. We offered
to the patient a treatment approach ap-
plying (off-label) the cyclooxygenase in-
hibitor celecoxib (Celebrex, Pfizer, 2 ×
200 mg daily oral).
Treatment with celecoxib was started
with 100 mg and increased by 100 mg
daily to reach the final dose of 400 mg
(2 × 200 mg daily) at d 4. This dose has
been continued for more than 5 months
and is well tolerated. Figure 2 illustrates
the clinical course before and during
celecoxib, including psychopathology
ratings that revealed a significant im-
provement of depressed as well as of
manic symptoms.
DISCUSSION
In our first molecular-genetic ap-
proach to alternating gene expression in
bipolar disorders, we used PBMC of a
woman with 16-year history of an ex-
treme form of rapid cycling, and obtained
an episode-specific gene expression pro-
Figure 1. (A) Strategy of episode-dependent gene shift detection using microchip analy-
sis. A three-step strategy was used to identify candidate genes that are expressed in an
episode-specific fashion: Eight blood samples were collected (always at 8:00 a.m.) in two
consecutive depressed and manic episodes on two consecutive days each. After screen-
ing by microarrays, the data set was submitted to two bioinformatic processing steps.
Genes were subtracted that differed between the two consecutive days within a particu-
lar episode (arbitrary daily variation). Further genes were excluded that were differentially
expressed within the two depressed or within the two manic episodes (arbitrary monthly
variation). The expression pattern of the remaining depressed and manic episode genes
was subsequently compared. (B–E) Episode-specific PBMC gene expression involves differ-
ent groups of genes. Genes found to be differentially expressed by microchip screening
were confirmed by qRT-PCR in all samples. Moreover, blood sampling was extended be-
yond the initial screening period, and regulated genes were again validated more than
one year later. Genes were grouped (B–E) according to biological categories. Each bar
represents mean ± SEM of 6 to 12 determinations from cDNAs obtained from PBMC on
different days in independent manic (n = 6; open bars) and depressed 
(n = 5; filled bars) episodes. The chart for hemoglobins contains an insert with hemoglobin
(protein) concentrations in whole blood (n = 7 samples of independent manic and de-
pressed episodes, respectively). Mean values were compared using independent Student
t test (two-tailed).
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file on an identical genetic background.
Our strategy was set up to minimize the
risk of identifying false positive genes,
due to daily or monthly variations in
gene expression that are disorder-unre-
lated. The gene expression differences
among episodes are small but signifi-
cant, and would not have been recog-
nized in a pool of patients or in compari-
son with healthy controls, due to
different genetic background and modi-
fiers of gene expression. In principle,
such an approach could be employed as
a screening strategy for genes in any
condition with temporal periodic behav-
ior, such as sleep or seasonal phenom-
ena/disorders.
Follow-up studies on larger numbers
of bipolar patients will have to follow,
to confirm the general disease-relevance
of the identified gene expression shifts.
Specifically, patients with a more typical
age of onset and course of bipolar dis-
ease will have to be screened. An age of
onset of 46 years and cycling over dec-
ades without euthymic episodes, as in
our patient, clearly is an exception (3–5).
The patient’s impairments comprise
psychopathological symptoms in combi-
nation with physical signs and symp-
toms, including the immune system, and
a variety of cognitive domains evident
upon neuropsychological testing. Ac-
cordingly, episode-specific gene expres-
sion involved different biological sys-
tems, such as blood, metabolism,
immune functions, as well as neuronal
genes, confirming rapid cycling as a sys-
temic disorder. Like all association stud-
ies, we can make no claim whether or
not a particular gene expression shift is
a cause or consequence of rapid cycling,
and whether similar gene expression
changes occur in the brain. Moreover, it
is currently unknown whether some of
the observed alterations in gene expres-
sion partly reflect the shifts in immune
cell subsets observed here.
Lamotrigine has been shown to alter
expression of certain genes, such as
GABA-A receptor β3 subunit in rat hip-
pocampal cells (13). During the entire
observation period (analysis and experi-
mental treatment) reported in this
paper, however, the patient was al-
ways on the same dose of lamotrigine
(episode-independent), making an in-
fluence of this pharmacological treat-
ment on the alternating gene expression
shown here very unlikely. No other
medication was used.
Some regulated genes identified in
PBMC are known to be expressed in the
nervous system. For example, NRG1 is a
neuronal growth factor regulating dif-
ferentiation, synaptogenesis, and myeli-
nation of the nervous system (14).
NRG1 also is expressed in activated
monocytes (15). Similarly, SPON2
(spondin, mindin) originally was char-
acterized in zebrafish as a protein in-
volved in outgrowth of hippocampal
Figure 2. Clinical course of psychopathology ratings before and during treatment with the cyclooxygenase inhibitor celecoxib. The
course of the Hamilton Depression Rating Scale (HAM-D) scores, the Young Mania Rating Scale (YMRS) scores, and the Positive and Neg-
ative Syndrome Scale (PANSS) scores, presented in line graphs, show a pronounced cycling pattern. Day 0 denotes start of celecoxib
intake. The magnitude of cyclic changes appears to gradually decrease during treatment. Bar graphs give scores (mean ± SEM) of n = 6
depressed and n = 6 manic episodes (two before and four after onset of treatment each). HAM-D score in depressed and YMRS score
in manic episodes decrease significantly upon treatment. Mean values are compared using independent Student t test (two-tailed).
M = manic episode, D = depressed episode.
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neurons (16). It is expressed abundantly
in lymphoid tissue and involved in in-
flammation (17).
Granzymes A and B (GZMA and
GZMB) and several natural killer cell re-
ceptors were higher in depressed epi-
sodes. We speculate that the observed
episode-specific gene expression con-
tributes to the pathogenesis seen in our
patient, including her allergic diathesis.
In contrast, the elevated globin gene
expression in manic episodes found here
may reflect a physiological counter-
regulation to the relative increase in ex-
tracellular fluid (and decrease in hemo-
globin level) due to massive drinking.
Interestingly, two genes were identi-
fied that are essential for prostaglandin
synthesis, PTGDS and AKR1C3. PTGDS
is preferentially expressed in the central
nervous system and mediates synthesis
of PGD2 from PGH2 (the cyclooxygenase-
mediated product of arachidonic acid),
and AKR1C3 mediates synthesis of
PGF2α from PGD2. PGF2α is a PPARγ an-
tagonist, in contrast to two other PGD2
metabolites that are spontaneously con-
verted from PGJ2: Δ
12-PGJ2 and 15-deoxy-
Δ12,14-PGJ2 that are PPARγ agonists.
Prostaglandin synthesis plays a pivotal
role in metabolic homeostasis, sleep
regulation, adipogenesis, allergic re-
sponse, and inflammation (18–22). Al-
tered levels of prostaglandins have
been detected in different body fluids
in patients with major affective disor-
ders (23–28). Also pharmacological evi-
dence (29–31) suggests that altered
prostaglandin metabolism may lead to
mood disorders. All this is consistent
with episode-specific differential gene
expression of PTGDS and AKR1C3 as
revealed in the present case.
Alterations in inflammatory markers
in serum of bipolar patients, such as cy-
tokines, c-reactive protein and compo-
nents of the complement system, have
been reported previously (32–38). There
might well be an interaction between
the prostaglandin system found to be
episodically regulated here, in the 
described case, and these inflammatory
molecules, also in the CNS (35,39,40).
Intriguingly, altered expression of
PTGDS marks the hibernation cycle, and
accumulation of prostaglandins during
hibernation season has been described in
hibernating animals (18,22). Based on our
molecular data, we speculate that the
rapid cycling syndrome in humans may
reflect an evolutionary ancient behav-
ioral program resembling the hibernation
cycle (with periodic eating, high psy-
chomotor activity and nesting behavior,
alternating with episodes of rest and
sleep) (41,42) that becomes pathologi-
cally re-activated by unknown triggers,
thereby creating rapid cycling.
The gene products involved in
prostaglandin metabolism might give
clues to potential treatment targets, but
to confirm their general relevance in
bipolar disease, more patients will have
to be examined for cycling-associated al-
terations in prostaglandin gene expres-
sion. Nevertheless, the positive result of
the clinical experiment with celecoxib in
our patient, showing considerable atten-
uation of both depressed and manic rat-
ing scores, supports a mediator role of
prostaglandins in rapid cycling. We are
fully aware of the limitation of a case re-
port in comparison to a clinical trial.
However, we note that the 16-year clini-
cal history of our patient has never
shown benefits from any of the many
pharmacological treatments, suggesting
that a potential placebo effect in our ex-
periment would be minor.
Supporting our findings, a recent
proof-of-concept trial in Germany in-
cluding patients with major monopolar
depression found beneficial effects on
mood upon 6-wk add-on treatment with
the cyclooxygenase-2 inhibitor celecoxib.
In contrast to our gene expression-based
“hibernation hypothesis of bipolar dis-
ease,” this trial was based on the hypoth-
esis that inflammatory processes might
be involved in the pathogenesis of de-
pression (43). Following the same inflam-
mation hypothesis of depression, another
small 6-wk study was performed in the
United States of America, exploring the
effect of celecoxib as adjunctive agent in
bipolar depression, also with promising
results (44). Bringing hibernation and
inflammation together, it is intriguing
to speculate that rapid cycling bipolar
disorders are characterized by episodic
self-limiting inflammatory processes
that, unlike other inflammatory condi-
tions in the brain, do not lead to overt
neurodegeneration.
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5. Morphological and cellular consequences of chronic 
neurodegeneration induced by an early unilateral 
parietal cryo-lesion and treatment by EPO 
 
5.1 Overview of project III 
In this project, we analyzed cellular consequences of chronic neurodegeneration 
using a mouse model of unilateral parietal cryo-lesion. We have previously 
shown that upon an early unilateral parietal lesion, mice developed a global 
progressive brain atrophy and cognitive impairment that could be prevented by 
early EPO treatment (Siren et al., 2006). Mice lesioned at 28 days showed gray 
matter loss and cognitive deficits in a hippocampus-dependent learning and 
memory task, Morris water maze, at a late time point i.e. 9 months after lesion. 
These neurodegenerative changes were completely prevented when the mice 
were treated with EPO (5000 IU/kg, i.p.) for 2 weeks every other day starting 
right after lesion.      
 
The cryo-lesion model in mice represents a mild traumatic insult at an early 
period in the life of a patient which might seem to be devoid of importance but 
might lead to the outcome of cognitive disorders like schizophrenia, Alzheimer’s 
Disease and Parkinson’s Disease (AbdelMalik et al., 2003; Bower et al., 2003; 
Koponen et al., 2002; Nemetz et al., 1999) when left untreated. Progressive 
cortical decline is a common phenomenon observed in these diseases. 
Therefore, it is important to understand what leads to the observed progressive 
pathology and how to mediate neuroprotection.  
 
In order to find out the mechanisms that might contribute to the outcome of global 
brain atrophy induced by this early lesion, we performed a detailed stereological 
analysis on anterior cingulate cortex and hippocampal subregions of 1 year old 
mice. This was the time point lesioned mice had already developed atrophy and 
cognitive deficits. The regions analyzed in this study were chosen according to 
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their importance for cognitive functions in rodents. The findings of the histological 
analysis were further supported by immunoblotting experiments. 
 
Unexpectedly, lesioned mice did not have differences with respect to their neuron 
and astrocyte numbers from sham-operated and EPO-treated mice i.e. they did 
not show any signs of neuronal loss or gliosis despite the fact that they had 
global brain matter loss and cognitive decline. This finding was consistent with 
the pathology seen in cognitive disorders like schizophrenia which is 
characterized by neurodegenerative changes accompanied by gray matter loss, 
ventricular enlargement, cognitive impairment in the absence of neuronal loss or 
gliosis. The relevance of our model for schizophrenia led us to explore the 
cellular consequences of global atrophy in more detail by focusing on subtypes of 
neurons and glia, which were consistently reported to be disturbed in 
schizophrenic post mortem brain tissue. 
 
The early lesion induced a bilateral increase in the number of IBA1 (ionized 
calcium-binding adapter molecule 1) positive microglia in anterior cingulate 
cortex and hippocampal subregions 24 hours after lesion. One dose of EPO 
treatment had already reduced the microglial number in respective areas in 
lesioned mice. Interestingly, when the mice were analyzed 11 months after 
lesion, they still had increased microglial numbers in hippocampus. This showed 
a lesion-induced persistent inflammatory response ongoing in the brains of 
lesioned mice. Similarly, EPO treated mice showed comparable microglia 
numbers to the sham operated mice.  
 
In 1 year old lesioned mice, we detected a subtle decrease in the number of 
Olig1 positive oligodendrocytes and decreased expression of myelin-related 
proteins, CNPase (cyclic nucleotide phosphodiesterase) and MBP (myelin basic 
protein) in hippocampus. Early EPO treatment led to an increase in the number 
of oligodendrocytes and prevented the decrease in myelin protein expression.  
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A detailed analysis of a subtype of neurons, the Parvalbumin positive GABAergic 
interneurons, revealed a bilateral increase in the relative number of these 
neurons in the dentate gyrus of lesioned mice at the age of 1 year. This increase 
in the relative number of GABAergic interneurons was further supported by the 
increase in the expression of 67 kDa isoform of GABA synthesizing enzyme, 
GAD67, in the contralateral hippocampus of lesioned mice detected by Western 
blot analysis. Once again, EPO-treated mice had comparable numbers of 
Parvalbumin positive GABAergic interneurons and similar levels of GAD67 
protein expression to the sham-operated mice.  
 
The role of synaptic loss in the outcome of brain atrophy and cognitive decline 
led us to count the number of synapsin1 positive presynaptic boutons in cingulate 
cortex and hippocampus of different groups of mice. Confocal analysis of 
presynaptic bouton number revealed no change between sham, lesioned and 
lesion+EPO groups. However, Western blot analysis of synapsin1 protein in 
contralateral hippocampus showed a decrease in the expression of this protein in 
lesioned mice compared to sham-operated and EPO-treated mice. The failure to 
document this finding histologically might be due to subtle changes between the 
groups which might be difficult to reveal with the methods used in this study.  
 
In summary, besides global cortical atrophy and cognitive impairment, lesion at 
an early age led to an increased inflammatory process assessed by an early and 
late increase in microglial numbers, decrease in the expression of myelin-
associated proteins, increased expression in determinants of GABAergic 
neurotransmission and decreased expression of a presynaptic protein, synapsin 
1. Interestingly, the late morphological and cellular consequences of this early 
lesion are similar to those observed in schizophrenic patients. In schizophrenia, 
increased microglial activation (van Berckel et al., 2008), decreased 
oligodendrocyte number and myelin-related gene expression (Davis and 
Haroutunian, 2003; Dracheva et al., 2006; Hakak et al., 2001; Hof et al., 2003), 
disturbances in Parvalbumin positive GABAergic interneurons as well as GAD67 
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protein expression (Akbarian et al., 1995; Bernstein et al., 2007; Volk et al., 
2000) and decreased expression of synapsin 1 protein (Vawter et al., 2002) have 
been reported in frontal and temporal regions of the patients. Moreover, parietal 
cortex, involved in sensorimotor and cognitive functions, has been reported to be 
the starting point of gray matter loss in early-onset schizophrenic patients 
(Thompson et al., 2001). 
  
The most striking finding in our study was that the morphological and 
pathological consequences of lesion could fully be prevented by early EPO 
treatment. With these findings we conclude that EPO treatment, besides its 
effects on improving cognition, could be effective in preventing the 
pathophysiology underlying cognitive disorders like schizophrenia and could be 
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Quantification of neurons and non-neuronal cells in cingulate cortex and hippocampal subregions of sham, lesion and 
lesion+EPO groups at 12 months of age did not reveal any significant differences. 
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Quantification of neurons and non-neuronal cells in cingulate cortex and hippocampal subregions of sham, lesion and 
lesion+EPO groups at 12 months of age did not reveal any significant differences. 
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In the first original publication, we investigated effects of EPO on cognition and 
mechanisms of how EPO improves cognitive functions and affects synaptic 
plasticity.  
 
We have shown that upon systemic EPO treatment for 3 weeks every other day, 
young healthy mice performed better in hippocampus-dependent memory tasks 
compared to the placebo treated group. This effect was observable 1 week after 
cessation of the treatment and interestingly, it was still maintained for another 3 
weeks of EPO treatment-free period. 3 weeks after cessation of EPO treatment, 
the hematocrit levels were comparable between the 2 mouse groups. This has 
once more shown that EPO’s effect on cognition is independent of its 
hematopoietic effect.  
 
We performed a detailed analysis to reveal the mechanisms of EPO-induced 
cognitive improvement by focusing on synaptic function. Slices obtained from 
mice treated with EPO for 3 weeks and killed 1 week after cessation of the 
treatment, were subjected to electrophysiological analysis. The most intriguing 
finding was EPO’s effect on increasing LTP. In parallel, magnitudes of STP and 
STD were significantly greater in EPO-treated mice. Moreover, whole-cell patch-
clamp recordings on CA1 pyramidal neurons showed that EPO increased the 
frequency of sIPSCs and decreased the frequency of sEPSCs. Thus, EPO 
modulated inhibitory and excitatory transmission inversely. Interestingly, number 
of synapses in hippocampal subregions did not differ between EPO- and 
placebo-treated animals. 
 
MEA recordings performed on primary hippocampal neurons in culture confirmed 
the direct EPO effect on neural cells. Primary hippocampal neurons isolated from 
mice at E17 were grown on MEA dishes and were treated with EPO every other 
day starting from day 5 in culture until day 25. Chronic application of EPO similar 
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to our in vivo approach resulted in prevention of a decrease in the number of 
silent channels upon maturation of the culture. Moreover, EPO treatment led to 
an increase in the number of bursting-channels. These results were in line with 
the in vivo data which also showed EPO’s favourable action on inhibitory 
transmission.  
 
To reveal EPO’s action on single cell level, we used autaptic hippocampal 
neurons treated with EPO at day 7 and subjected to electrophysiological and 
immunocytochemical analyses on days 9-14. Single EPO addition led to a 
decrease in EPSC amplitude and readily-releasable pool size without affecting 
the total number of synapses.   
 
Based on these findings, we conclude that, in addition to its effect on improving 
cognition under pathological conditions, EPO leads to an increase in 
hippocampus-dependent memory in the healthy brain. EPO’s mechanism of 
action on synaptic plasticity seems to be in favor of inhibitory transmission 
without affecting the total number of synapses. We hypothesize that EPO 
modulates synaptic plasticity by increasing the activity of selected networks while 
keeping the others silent.   
 
In the second original publication, we focused on a rare form of bipolar disorder, 
rapid cycling syndrome, and analyzed gene expression changes in different 
disease episodes in a rapid cycling patient. Depending on the gene expression 
results, we performed a clinical experiment offering a new treatment approach for 
our patient. 
 
RNA isolated from PBMC collected at different manic and depressed episodes 
from the patient was subjected to a detailed microarray analysis. Genes selected 
based on microarray analysis, after excluding the ones that showed daily and 
monthly variations, were confirmed by qRT-PCR. With this approach, we 
identified a group of genes that showed alterations in different episodes of the 
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disease. These included genes that were involved in prostaglandin metabolism, 
neurodevelopment, immune and hematopoietic systems.  
 
Based on our hypothesis that cyclic alterations in rapid cycling syndrome might 
reflect an ancient evolutionary program similar to hibernation cycle of mammals 
which is characterized by periodic eating, drinking, sleep and altered metabolism 
and that this program might be reactivated under certain pathological conditions, 
we focused on genes involved in prostaglandin synthesis which has been shown 
to have important roles in hibernation cycle of mammals (O'Hara et al., 1999). 
We performed a clinical experiment by offering the patient a treatment approach 
using a cyclooxygenase inhibitor celecoxib. Treatment with celecoxib over 5 
months led to stabilization of manic and depressed episodes by reducing manic 
and depressed rating scores. Keeping in mind that celecoxib has been the only 
effective drug for our patient who has a 16 year disease history, we believe that 
more patients should be tested for the efficacy of this treatment in rapid cycling 
syndrome and to reveal the role of prostaglandin metabolism in this disorder. 
 
In the third study, we investigated the mechanisms of atrophy and EPO-induced 
recovery upon a discrete cryo-lesion performed on the right parietal cortex of 
juvenile mice.  
 
Mice lesioned at an early age (28 days old) developed a progressive 
neurodegenerative process characterized by gray matter loss, ventricular 
enlargement and cognitive decline which was highly significant 9 months after 
injury. EPO treatment right after the lesion for 2 weeks every other day prevented 
lesion-induced brain atrophy and cognitive decline (Siren et al., 2006). In order to 
investigate the mechanisms of lesion-induced atrophy, we performed a detailed 
histological analysis based on stereology on 1 year old mice. At this age, brain 
atrophy and cognitive decline induced by lesion were already evident.  
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Histological analysis was performed on anterior cingulate cortex and subregions 
of hippocampus. Interestingly, despite progressive global brain atrophy, lesioned 
mice had comparable number of neurons and astrocytes to the sham-operated 
and EPO-treated mice. This indicated a degenerative process going on without 
neuronal loss and gliosis similar to the characterization of brain atrophy in 
schizophrenic patients. We next focused on differences in neuronal and glial 
subpopulations between different groups of mice. 24 hours after a discrete 
unilateral lesion, a bilateral increase in the number of microglia was observed in 
all brain areas investigated. Interestingly, 11 months after lesion, increase in the 
microglial number was still observable in hippocampus. This showed a chronic 
persistent inflammatory response going on in the brains of lesioned mice. Early 
EPO treatment prevented the increase in microglial number at both time points. 
Lesioned mice at the age of 1 year had a slight reduction in the number of 
oligodendrocytes accompanied by reduced expression in myelin proteins. EPO 
treatment increased the number of oligodendrocytes and prevented the reduction 
in myelin protein expression. Moreover, EPO prevented lesion-induced increase 
in the ratio of Parvalbumin positive interneurons and GAD67 protein expression. 
Decrease in the expression of synapsin 1 protein upon lesion was also prevented 
by early EPO treatment. 
 
Morphological and pathological consequences of an early brain injury are similar 
to those observed in schizophrenic brain. Thus, our parietal injury model serves a 
good basis to study the mechanisms of progressive atrophy and EPO treatment 
in cognitive disorders such as schizophrenia. Based on our findings, we conclude 
that EPO treatment in cognitive disorders might be beneficial in preventing the 
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Germany 
The Annual Global Conference on Neuroprotection and 
Neuroregeneration 
Poster presentation 
6-9 Sept 2006   
Luebeck, Germany 
 
7th International Luebeck Conference on the 
Pathophysiology and Pharmacology of Erythropoietin 
and other Hemopoietic Growth Factors 
Poster presentation 
17-20 February 2005 
Göttingen, Germany 
30th Göttingen Neurobiology Conference 
 
15-16 September 2005 
14-15 September 2007 
18-19 September 2008 
Göttingen, Germany 
International Symposia on Schizophrenia of the 
Göttingen Research Association for Schizophrenia 



















Sports (gymnastics, swimming-licensed in highschool, 
basketball-licensed in highschool, step-licensed in 
university, windsurfing) 
Reading 
 
